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PREFACE 
This occasional paper is the result of a study funded by IP Australia 
looking into the effects of the High Court’s decision in D’Arcy v Myriad 
Genetics [2015] HCA 35 on the cost of genetic diagnostic testing in 
Australia. The High Court handed down its decision on 7 October 2015, 
and this study sought to ascertain whether there is any basis to conclude 
that the decision, which invalidated Myriad’s patent over the BRCA gene, 
has had a discernible impact on the cost of testing. In addition to 
reviewing the extensive literature that has amassed in relation to patents 
and their impact on genetic diagnostic testing, the project involved 
detailed analysis of relevant case law and interviews with those involved 
in genetic testing in Australia. 
We extend our sincere thanks to IP Australia for enabling this important 
research. This study was funded by IP Australia but the results reported 
in no way reflect the views of IP Australia or the Australian Government. 
We are indebted to all of our participants for so generously giving their 
time to be interviewed. We also thank Bryanna Workman for her 
invaluable work in editing and putting this occasional paper together.  
A summarised version of this occasional paper has been accepted for 
publication in the European Intellectual Property Review: 
Jane Nielsen and Dianne Nicol, ‘The Myriad Litigation and 
Genetic Diagnostic Testing in Australia’ (2019) European 
Intellectual Property Review (forthcoming). 
We have permission from the editors of the European Intellectual 
Property Review to publish material from that article in this occasional 
paper. 
The authors have no conflicting interests. To the best of our knowledge 
the law as stated in this occasional paper is current as at 31 December 
2018. 
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CHAPTER 1 
INTRODUCTION 
   
This occasional paper provides an assessment of whether the decision of 
the High Court of Australia in D’Arcy v Myriad Genetics Inc (‘D’Arcy’)1 has 
had any significant impact on the cost of diagnostic testing in this 
country. Our hypothesis in undertaking the study was that the decision 
would have had very little impact on the pricing of genetic diagnostic 
testing in Australia, based on our past research in this area and our 
knowledge of the legal and business landscape. In testing this hypothesis, 
we first briefly outline the nature of the patent claims in issue in D’Arcy 
and other relevant cases, the law relating to the patentable subject 
matter inquiry, and the details of the D’Arcy decision and its sequelae.  
We then provide a brief overview of the genetic diagnostic testing 
industry and summarise earlier research findings on patent subsistence, 
enforcement and costs to providers of genetic diagnostic testing services. 
Next, we turn to the empirical aspect of our study, which has been 
designed to provide evidence of the extent to which the D’Arcy decision 
has had, or is likely to have an impact on the current costs of genetic 
diagnostic testing services. This evidence takes the form of data collected 
from interviews with individuals from facilities involved in the provision 
of genetic diagnostic testing services, and individuals responsible for 
setting fees and reimbursement schedules for the provision of genetic 
diagnostic testing services in state and federal health departments and 
the private sector. In the last section of the occasional paper, we consider 
other implications of patents claiming rights to nucleotide sequences and 
to other subject matter (particularly method claims), both for the genetic 
diagnostic testing sector and for other industry sectors.  
To be clear, we have focused solely on the issue of cost in this study – 
primarily whether invalidation of the patents held by Myriad Genetics, 
Inc (‘Myriad’) could have the effect of decreasing the cost burden on 
providers of genetic diagnostic testing by invalidating patents that 
ostensibly have been responsible for creating that same cost burden. We 
have not undertaken an analysis of the purported benefits arising from 
the grant of Australian patents to Myriad (nor other nucleotide sequence 
and method patents). This is beyond the scope of this study. The question 
                                                           
1  D’Arcy v Myriad Genetics Inc (2015) 258 CLR 334; [2015] HCA 35 (7 October 2015) 
(‘D’Arcy’). 
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of whether patents of this nature contribute to the incentive function of 
the patent system is a vexed one, which has not been resolved 
empirically in any jurisdiction.  
In the context of the D’Arcy case, we note that, over a number of years, 
Myriad filed various patents over the BRCA1 and BRCA2 nucleotide 
sequences and their methods of use in multiple jurisdictions.2 Discovery 
of the link between BRCA1 and BRCA2 mutations and increased risk of 
developing breast and ovarian cancer was an important development. It 
led to the development of genetic diagnostic tests that are used to 
identify whether individual patients possess mutations in their BRCA 
nucleotide sequences that are known to be associated with a much 
higher than average risk of developing breast or ovarian cancer. 
Diagnostic tests can also be used to detect BRCA mutations in breast 
cancer tumour cells, facilitating decision-making about treatment 
options that are only available to patients who test positive to the 
relevant mutations.  
Myriad acquired particular benefit from the exercise of its patent rights 
in the US (though, as we will see, less so in Australia) by insisting on 
exclusivity in provision of BRCA testing. As a result, Myriad now possesses 
a database of sequence information that is far superior to public 
databases, or databases of any of its competitors, in that there is a much 
lower percentage of sequence variants of unknown significance. This 
means that Myriad can give a much more accurate report on the 
presence or absence of deleterious mutations linked with increased 
susceptibility to the development of breast and ovarian cancers. Quite 
whether this is of benefit to society is another question entirely. Those 
individuals receiving BRCA test results from Myriad may have a more 
accurate diagnosis than if they go to another provider. The problem is 
that there is no indication that Myriad is prepared to give open access to 
this database, providing it with a competitive advantage going beyond 
the term of its (now invalidated) US patents, and potentially leading to 
significant disadvantage to those patients who cannot access Myriad 
tests.3 Although some anecdotal comments suggest that the quality of 
                                                           
2  We note that the terms nucleotide sequences, DNA, genes and nucleic acids are 
used interchangeably in the primary and secondary literature. We have adopted the 
terminology of nucleotide sequences in this report, except when quoting or 
referring to sources that use different terminology.  
3  We discuss this further in Jane Nielsen and Dianne Nicol, ‘The Legal Vacuum 
Surrounding Access to Gene-Based Materials and Data’ (2016) 24 Journal of Law 
and Medicine 72. 
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data held in public databases will soon be on par with Myriad’s, a recent 
analysis suggests that they are still a long way apart.4 
                                                           
4  William Gradishar et al, ‘Clinical Variant Classification: A Comparison of Public 
Databases and a Commercial Testing Laboratory’ (2017) 22(7) Oncologist 797 doi: 
10.1634/theoncologist.2016-0431. 
  4 
CHAPTER 2 
METHODS 
 
This study utilised mixed methods in an effort to drill down on whether 
D’Arcy has had a measurable impact on the cost of genetic diagnostic 
testing in Australia. Methods included:  
• detailed searches of relevant legal, IP and other databases and 
websites for information on the D’Arcy decision and the makeup 
of the Australian genetic diagnostic testing industry; 
• doctrinal analysis of the D’Arcy decision and other case law; 
• detailed review of empirical literature considering the impact of 
nucleotide sequence patents on the delivery of genetic 
diagnostic testing; and 
• interviews with key stakeholders in the Australian genetic 
diagnostic sector. 
The interview component of this study involved interviews with key 
personnel from the genetic diagnostic testing industry in Australia. Ethics 
approval for this interview component was granted by the Tasmania 
Statewide Human Research Ethics Committee.5 Participants were 
selected using purposive and critical case sampling techniques. Labs that 
perform genetic diagnostic tests were identified through the databases 
of the Royal College of Pathologists of Australia and the National 
Association of Testing Authorities. These databases are publicly available 
and contained on the websites of these organisations. The contacts 
obtained were cross-checked to assist in identifying relevant personnel 
within each organisation. The total number of labs listed was 45: this 
included both public and privately-run labs, and was based on the listing 
contained in Table 3 of this occasional paper.  
A significant number of the labs listed were contacted: in all, 40 emails 
were sent to relevant personnel. In some cases, more than one person 
within an organisation was contacted where it became apparent that an 
alternative contact would be more likely to yield an interview. We were 
particularly interested in speaking with participants from public labs 
                                                           
5  Tasmania Statewide Human Research Ethics Committee Minimal Risk Application 
H0016230, 30 November 2016. 
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offering a large number of available tests. Labs offering BRCA testing 
were also targeted given our specific interest in the effect of the D’Arcy 
decision. State health department contacts were identified by internet 
searches. All of the private providers were contacted. We continued to 
seek interviews until thematic saturation was reached. Interviews were 
based on a number of interview themes developed around the core 
research question (see Appendix A). Using our analysis of literature, case 
law and previous empirical studies, we were able to derive a conceptual 
framework against which to conduct iterative data analysis. De-identified 
transcripts were coded and analysed. Thematic and latent content 
analysis techniques were employed to inductively analyse our data,6 with 
findings from interviews being progressively fed into subsequent 
interviews. 
Sixteen interviews were conducted. Table 1 contains a categorisation of 
interviewees and demonstrates a fairly even spread across industry 
sectors. 
Table 1: Categories of interviewees 
                                                           
6  Maria J Mayan, Essentials of Qualitative Inquiry (Left Coast Press, 2009). 
 State health department 
Pathology 
labs in 
public 
hospitals 
Standalone public 
pathology labs 
and other non-
profit providers 
Research 
institutes/ 
universities 
Private 
companies 
Number 
interviewed 3 4 3 3 3 
Number 
involved in 
provision of 
BRCA 
testing 
2 1 3 2 1 
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CHAPTER 3  
THE D’ARCY DECISION AND ITS BROADER IMPACT  
 
3.1  PATENT CLAIMS IN ISSUE  
As intimated in the introduction to this occasional paper, our analysis 
focuses primarily on two types of patent claims, nucleotide sequence 
claims and method claims. Critically, the courts in D’Arcy considered only 
nucleotide sequence claims because these were the only claims that 
were challenged by the applicant. We do not know the exact reason why 
the applicants chose only these claims. However, we have seen in our 
earlier work and in our current round of interviews that there is a deep-
seated view among Australian test providers that patents should not be 
available for isolated nucleotide sequences. This concern does not 
appear to extend to claims relating to methods of diagnosis, even though 
they, like sequence claims, can be used to provide exclusivity in the 
genetic diagnostic testing market. In contrast, in US litigation 
corresponding with the Australian D’Arcy case, the applicants challenged 
both sequence and method claims. However, like the D’Arcy decision, the 
final decision by the US Supreme Court in this case, Association for 
Molecular Pathology v Myriad Genetics Inc (‘AMP’)7 concerned only 
nucleotide sequence claims. Moreover, neither court specifically ruled 
on modified/human made sequences (other than cDNA sequences, 
which are explained below); sequences incorporated into 
pharmaceutical products; other products of nature; or methods.  
3.1.1 Nucleotide sequence claims 
Within the set of nucleotide sequence claims that were included in 
Myriad’s patents, a distinction can be drawn between isolated nucleotide 
sequences (sometimes referred to as gDNA) and complementary DNA 
(cDNA). An isolated sequence is a sequence of nucleotides derived from 
a DNA molecule that has been removed from its normal cellular 
environment, without modification.8 In D’Arcy, some of the isolated 
                                                           
7  Association for Molecular Pathology v Myriad Genetics Inc, 133 US 2107 (2013) 
(‘AMP’). 
8  D’Arcy (2015) 258 CLR 334, 360. 
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nucleotide sequence claims were to the entire genes, whereas others 
claimed much shorter sequences occurring within the genes.9 
In contrast to an isolated nucleotide sequence, cDNA is not precisely the 
same as a nucleotide sequence existing in nature, since it is reverse 
transcribed from messenger RNA.10 Messenger RNA (mRNA) is an 
intermediary in the process of formation of protein based on the 
information contained in genes. In the process of transcription from 
genes to mRNA, parts of the nucleotide sequence included in the genes 
(the introns) are removed. As such, cDNA only includes the active parts 
of the nucleotide sequence in genes used in protein formation (exons). 
Despite these informational differences, the functions of the isolated 
nucleotide sequences and cDNA derived from a particular gene are 
essentially the same, in that both are capable of coding for the same 
protein.11 
The principal nucleotide sequence claim in D’Arcy that was in dispute was 
claim 1: 
[a]n isolated nucleic acid coding for a mutant or polymorphic 
BRCA1 polypeptide, said nucleic acid containing in comparison 
to the BRCA1 polypeptide encoding sequence set forth in SEQ.ID 
No:1 one or more mutations or polymorphisms selected from 
the mutations set forth in Tables 12, 12A and 14 and the 
polymorphisms set forth in Tables 18 and 19.  
The patent specification explains that a combination of sequences 
obtained from cDNA clones, hybrid selection sequences and amplified 
PCR12 products allowed construction of a composite full length sequence 
for BRCA1 cDNA designated SEQ ID No:1.13 Even though the claimed 
sequence was artificially constructed, the High Court held that it was 
invalid because it contained no new information. Rather, it was ‘the same 
                                                           
9  Dianne Nicol, ‘Myriad Genetics and the Remaining Uncertainty for Biotechnology 
Inventions’ in Charles Lawson and Berris Charnley (eds), Intellectual Property and 
Genetically Modified Organisms: A Convergence in Laws (Ashgate, 2015) 123, 129–
130.  
10  Ibid. 
11  Ibid. 
12  PCR is the polymerase chain reaction, a foundational technique that enabled 
amplification of DNA strands for use in experimentation: Randall K Saiki et al, 
‘Enzymatic Amplification of Beta-globin Genomic Sequences and Restriction Site 
Analysis for Diagnosis of Sickle Cell Anemia’ (1985) 230 Science 1350; Kary Mullis, 
‘The Unusual Origin of the Polymerase Chain Reaction’ (April 1990) Scientific 
American 56. 
13  D’Arcy (2015) 258 CLR 334, 364. 
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information as that contained in the DNA of the person from which [it] 
was isolated’.14 
In AMP nine nucleotide sequence claims from three patents were in 
issue.15 The Court stated that claims 1, 2, 5, and 6 from a patent they 
identified as the ’282 patent were representative. Of these, claims 1 and 
5 referred to gDNA whereas 2 and 6 were cDNA claims. Claim 1 was 
similar, but not identical to its equivalent in Australia: an isolated DNA 
coding for a BRCA1 polypeptide, said polypeptide having the amino acid 
sequence set forth in SEQ ID NO:2.16 Claim 2 was in similar terms, but 
only referenced the cDNA sequence. Claims 5 and 6 claimed only a subset 
of the nucleotides in the BRCA gene: an isolated DNA having at least 15 
nucleotides of the DNA of claim 1 (or 2). The Supreme Court found that 
claims 1 and 5 were invalid, but not claims 2 and 6. These claims were 
held to be valid by the Supreme Court because ‘creation of a cDNA 
sequence from mRNA results in an exons-only molecule that is not 
naturally occurring.’17 The Court found that something unquestionably 
new is created when cDNA is made. Therefore, cDNA did not fall within 
the ‘product of nature’ exception, and was patent eligible.  
3.1.2 Method claims  
As stated above, method claims were not in issue in D’Arcy. In contrast, 
two types of method claims were in issue in AMP: broad methods of 
diagnosis, underlaid by sequence information; and specific methods of 
diagnosis, also underlaid by sequence information. The validity of these 
claims was determined on two occasions by the Court of Appeals of the 
Federal Circuit.18 The decisions of the Federal Circuit in relation to the 
method claims were not appealed by either party in the Supreme Court. 
The broad claims were to methods of analysing or comparing a patient’s 
BRCA sequence with the normal, or wild type, sequence to identify the 
                                                           
14  Ibid 371. 
15  AMP, 133 US 2107, 2113 (2013).  
16  Ibid 2113. 
17  Ibid 2119. 
18  Association for Molecular Pathology v United States Patent and Trademark Office, 
653 F 3d 1329, 1334 (Fed Cir, 2011); Association for Molecular Pathology v United 
States Patent and Trademark Office, 689 F 3d 1303, 1335 (Fed Cir, 2012). The 
Federal Circuit was required to hear the case a second time because the US 
Supreme Court would not grant certiorari before the lower court had the 
opportunity to consider whether the intervening Supreme Court decision in Mayo 
Collaborative Services v Prometheus Laboratories Inc, 566 US 66 (2012) had any 
bearing on its decision in AMP. In essence, the original decision of the Federal 
Circuit remained unchanged in the second decision. 
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presence of cancer predisposing mutations, whether in the form of 
germline mutations in the patient’s cells, or specific somatic mutations in 
tumour cells.19 The courts considered claim 1 of the patents they referred 
to as the ‘999 and ‘001 patents to be representative of all but one of the 
method claims. 
Claim 1 of the ‘999 patent provided: 
[a] method for detecting a germline alteration in a BRCA1 gene, 
said alteration selected from the group consisting of the 
alterations set forth in Tables 12A, 14, 18 or 19 in a human 
which comprises analyzing a sequence of a BRCA1 gene or 
BRCA1 RNA from a human sample or analyzing a sequence of 
BRCA1 cDNA made from mRNA from said human sample with 
the proviso that said germline alteration is not a deletion of 4 
nucleotides corresponding to base numbers 4184-4187 of SEQ 
ID NO: 1.20 
Claim 1 of the ‘001 patent provided: 
[a] method for screening a tumor sample from a human subject 
for a somatic alteration in a BRCA1 gene in said tumor which 
comprises … comparing a first sequence selected from the 
group consisting of a BRCA1 gene from said tumor sample, 
BRCA1 RNA from said tumor sample and BRCA1 cDNA made 
from mRNA from said tumor sample with a second sequence 
selected from the group consisting of BRCA1 gene from a 
nontumor sample of said subject, BRCA1 RNA from said 
nontumor sample and BRCA1 cDNA made from mRNA from 
said nontumor sample, wherein a difference in the sequence of 
the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA from said tumor 
sample from the sequence of the BRCA1 gene, BRCA1 RNA or 
BRCA1 cDNA from said nontumor sample indicates a somatic 
alteration in the BRCA1 gene in said tumor sample.21 
These claims were found to be too broad in both the first and second 
decisions of the Federal Circuit. In the first decision Justice Lourie stated 
that they were not patentable because they claimed only abstract mental 
processes, and that the comparison between the two sequences can be 
                                                           
19  Association for Molecular Pathology v United States Patent and Trademark Office, 
653 F 3d 1329, 1334 (Fed Cir, 2011). 
20  Ibid. 
21  Ibid 1335. 
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accomplished by mere inspection alone, not through any determination 
or transformative step.22 This was affirmed in the second decision.23 
More specificity and the inclusion of transformative steps can make a 
method patent valid. In the Federal Circuit Court decision, claim 20 of the 
patent referred to as ‘282 was distinguished from the other method 
claims. It provided: 
[a] method for screening potential cancer therapeutics which 
comprises: growing a transformed eukaryotic host cell 
containing an altered BRCA1 gene causing cancer in the 
presence of a compound suspected of being a cancer 
therapeutic, growing said transformed eukaryotic host cell in 
the absence of said compound, determining the rate of growth 
of said host cell in the presence of said compound and the rate 
of growth of said host cell in the absence of said compound and 
comparing the growth rate of said host cells, wherein a slower 
rate of growth of said host cell in the presence of said 
compound is indicative of a cancer therapeutic.24 
This claim was held patent eligible in both decisions of the Federal 
Circuit.25 It was found valid because ‘in addition to the step of comparing 
the cells' growth rates, the claim also recites the steps of growing 
transformed cells and determining those growth rates.’26 These steps 
were held to be transformative.27 It was concluded that the product of 
claim 20 was a transformed cell, man-made and not naturally occurring.28 
Table 2 provides a summary of the four types of claims in issue in the US 
litigation, and the holdings of the courts at each decision level. 29 
  
                                                           
22  Ibid 1355.  
23  Association for Molecular Pathology v United States Patent and Trademark Office, 
689 F 3d 1303, 1335 (Fed Cir, 2012). 
24  Association for Molecular Pathology v United States Patent and Trademark Office, 
653 F 3d 1329, 1335 (Fed Cir, 2011). 
25  First Federal Circuit decision: Association for Molecular Pathology v United States 
Patent and Trademark Office, 653 F 3d 1329, 1358 (Fed Cir, 2011); Second decision: 
Association for Molecular Pathology v United States Patent and Trademark Office, 
689 F 3d 1303, 1337 (Fed Cir, 2012). 
26  Association for Molecular Pathology v United States Patent and Trademark Office, 
689 F 3d 1303, 1335 (Fed Cir, 2012). 
27  Ibid 1333–4. 
28  Ibid. 
29 Extracted from: Nicol, above n 9, 130–1. 
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Table 2: Summary of decisions in the AMP case 
 
 
Isolated 
sequences 
identical to 
those in nature 
(gDNA) 
Synthetic 
sequences 
complementary 
to RNA (cDNA) 
Methods of 
comparing or 
analysing 
DNA 
sequences 
Method for 
screening 
potential 
cancer 
therapeutics 
AMP First 
Instance 
Sweet J 
Invalid – products 
of nature. Physical 
embodiment of 
information – 
structural and 
functional 
differences 
irrelevant 
Not distinguished 
from gDNA 
Invalid – 
abstract mental 
processes 
No machine or 
transformation1 
Invalid – basic 
scientific 
principle 
No machine or 
transformation 
AMP Federal 
Circuit, #1 
and #2 
Lourie J 
(majority) 
Valid – markedly 
different chemical 
identity and 
nature – broken 
covalent bonds 
Valid – markedly 
different 
Invalid – 
abstract mental 
processes. No 
additional 
transformative 
steps included 
in the claims 
Valid – 
transformative. 
Growing and 
determining 
growth rates of 
transformed 
cells 
AMP Federal 
Circuit #1 and 
#2 
Moore J 
(majority) 
Valid – chemical 
differences are 
not enough and 
no new utility – 
not a blank canvas 
– leave intact 
settled 
expectations 
Valid – joined 
majority 
Invalid – joined 
majority 
Valid – joined 
majority 
AMP Federal 
Circuit #1 and 
#2 
Bryson J 
(dissent in 
part) 
Invalid – products 
of nature – same 
structurally and 
functionally – the 
only changes 
were incidental to 
extraction 
Generally valid – 
agreed with the 
majority except 
for claims to short 
strands 
indistinguishable 
from gDNA. 
Invalid – joined 
majority 
Valid – joined 
majority 
AMP SCOTUS 
Invalid – products 
of nature. 
Isolation from 
surrounding 
genetic material is 
not enough 
Generally valid – 
markedly 
different, except 
for the claims 
identified by 
Bryson J 
Not decided Not decided 
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3.2 PATENTABILITY OF NUCLEOTIDE SEQUENCES PRE-D’ARCY 
Prior to the D’Arcy decision, nucleotide sequences were generally 
considered patentable if they satisfied legislative requirements included 
in the Patents Act 1990 (Cth) (‘Patents Act’), (as were claims to methods 
of diagnosis). A patentable invention, as defined in the Patents Act, 
requires inter alia the subject matter of a claim to be a ‘manner of new 
manufacture’ within the meaning of section 6 of the Statute of 
Monopolies 1623. Prior to D’Arcy, the seminal authority on the meaning 
of manner of manufacture was National Research Development 
Corporation v Commissioner of Patents in 1959 (‘NRDC’).30  The two key 
elements required for satisfaction of the manner of manufacture 
requirement articulated by the High Court in this case were: ‘is it an 
artificially created state of affairs of economic utility?’31 As the 
biotechnology industry emerged in the 1980s and 1990s it was widely 
thought that genetic materials made in the lab satisfied this requirement 
because they were isolated from the natural environment and had 
economic value to the Australian industry and to healthcare generally.32  
Kirin-Amgen Inc v Board of Regents of University of Washington in 1995 
was the first reported decision of the Australian Patent Office which 
considered whether to allow a patent claim to isolated nucleotide 
sequences.33  The Deputy Commissioner of Patents found that purified 
and isolated nucleotide sequences were an artificially created state of 
affairs.34 Subsequent to this case, granting patents on isolated nucleotide 
sequences became an established practice.35 Prior to D’Arcy, the 
Australian courts were not provided with the opportunity to determine 
whether or not subject matter of this nature satisfied the manner of 
manufacture requirement. 
                                                           
30  National Research Development Corporation v Commissioner of Patents (1959) 102 
CLR 252 (‘NRDC’). 
31  Ibid 276. 
32  Dianne Nicol, ‘Should Human Genes be Patentable Inventions under Australian 
Patent Law?’ (1996) 3 Journal of Law and Medicine 231, 237. 
33  Kirin-Amgen Inc v Board of Regents of University of Washington (1995) 33 IPR 557. 
34  Ibid 569.  
35  Emanuela Gambini, ‘In the Aftermath of D'Arcy v. Myriad Genetics Inc: Patenting 
Isolated Nucleic Acids in Australia’ (2016) 7(2) European Journal of Risk Regulation 
451, 457. 
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3.3 LAW REFORM INQUIRIES 
One of the key issues for consideration in D’Arcy was whether according 
patentability to the class of claim at issue would involve law making of a 
kind which should be done by the legislature. Myriad had submitted that 
the decisions by the legislature and other government bodies not to 
specifically exclude nucleotide sequences from patentability meant that 
they should be patentable. One of the first of such discussions occurred 
in 1990 where the Senate rejected an amendment to the Patents Bill 
1990 (Cth) proposed by Senator Coulter, which would have had the effect 
of excluding nucleotide sequences and genetically modified organisms 
from patentability.36 The rationale provided for rejecting the amendment 
was that it would hinder research and development of new technology 
in the medical and pharmaceutical fields.37  
In 2004, the Australian Law Reform Commission released their Report, 
Genes and Ingenuity: Gene Patenting and Human Health, concluding that 
‘a new approach to the patentability of genetic materials is not 
warranted at this stage in the development of the patent system’.38 The 
ALRC found that the problem regarding access to healthcare was not in 
the patenting of genetic material and technologies per se, but in the way 
in which those patents may be commercially exploited, including through 
aggressive licensing.39 
In November 2010, the Senate Community Affairs References Committee 
published their Report, Gene Patents, following a referral from the 
Australian Senate. Concerns had been raised in the Senate about the risk 
that a small Melbourne biotechnology company, Genetic Technologies 
Ltd (‘GTG’), would enforce patents relating to BRCA1 and BRCA2.40 GTG 
held an exclusive licence within Australia and New Zealand to exploit the 
BRCA1 and BRCA2-related patents owned by Myriad. The Committee 
discussed the proposal for an express prohibition on nucleotide 
sequence patents but found that a lack of relevant data meant they were 
                                                           
36  Commonwealth, Parliamentary Debates, Senate, 17 September 1990, 2478–82 
(John Coulter). 
37  Commonwealth, Parliamentary Debates, House of Representatives, 16 October 
1990, 2948 (Geoffrey Prosser). 
38  Australian Law Reform Commission, Genes and Ingenuity: Gene Patenting and 
Human Health, Report No 99 (2004) [6.53].  
39  Ibid [504]. 
40  Community Affairs References Committee, Parliament of Australia, Gene Patents 
(2010).  
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unable to conclude whether patents did have an adverse impact on 
healthcare. As such, they were reluctant to support the introduction of 
an express exclusion at that time.  
Also in 2010, the Advisory Council on Intellectual Property released their 
Report, Patentable Subject Matter, which aligned closely with the 
Community Affairs References Committee Report. The Council found no 
persuasive case to introduce a specific exclusion to prevent the patenting 
of nucleotide sequences and genetic products and declined to 
recommend the introduction of such a specific exclusion.41 
In September 2011, the Legal and Constitutional Affairs Legislation 
Committee completed their Report considering whether to pass the 
Patent Amendment (Human Genes and Biological Materials) Bill 2010 
(Cth).42 The Bill was introduced into the Senate on 24 November 2010 by 
Senators Coonan, Heffernan, Siewert and Xenophon. The purpose of the 
Bill was to amend the Patents Act to exclude human genes and biological 
materials as they exist in nature, from patent eligibility.43 After receiving 
122 submissions and conducting two public hearings, the Committee 
recommended that the Senate should not pass the Bill. This was mostly 
due to ambiguities in the drafting which meant that the Bill would not 
meet its intention, and could have widespread unintended consequences 
as well as negatively affect innovation.  
Cumulatively, these Reports show a clear lack of support for an express 
exclusion of nucleotide sequences. In contrast, they did support other 
reforms to the Patents Act. In particular, they led to the introduction of 
an experimental use exemption in 2012, which clarified that experiments 
on patented inventions do not constitute patent infringement.44 Other 
amendments were made in the same amending Act to the inventive step 
and utility requirements, but the manner of manufacture requirement 
remained untouched. 
 
                                                           
41  Advisory Council on Intellectual Property, Commonwealth of Australia, ‘Patentable 
Subject Matter: Final Report’ (2010) 60.  
42  Legal and Constitutional Affairs Legislation Committee, Parliament of Australia, 
Patent Amendment (Human Genes and Biological Materials) Bill 2010 (2011). 
43  Ibid 1.1. 
44  Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth) s 119C.  
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3.4 THE D’ARCY CASE 
3.4.1  Case history  
The core Australian BRCA1 patent that was the subject of challenge in the 
D’Arcy case was entitled ‘In vivo mutations and polymorphisms in the 
17q-linked breast and ovarian cancer susceptibility gene’, with patent 
number 686004 (‘the 686004 patent’), which had a priority date of 12 
August 1994. The patent application was filed in Australia on 11 August 
1995 and expired on 11 August 2015, almost two months before the 
D’Arcy decision was handed down by the High Court.  
In May 2003, Myriad granted GTG its exclusive licence for the use of 
Myriad’s patents. In 2003 and again in 2008, GTG threatened to enforce 
their patent rights against public laboratories and research bodies, 
seeking to prevent these organisations from engaging in any further 
testing for the BRCA mutations.45 This resulted in a public backlash. As a 
result of this public outcry, GTG stated in a report to shareholders on 9 
July 2003 that it was not seeking to enforce its rights over the genes and 
that the BRCA genes ‘are our gift to the Australian people’.46 After GTG 
attempted to change its policy to enforce its patent rights in 2008, the 
company then announced that it had reviewed its decision and ‘resolved 
to immediately revert to its original decision to allow other labs in 
Australia to freely perform BRCA testing’.47 
In 2010 Cancer Voices Australia and Yvonne D’Arcy launched action 
against Myriad in the Federal Court challenging the 686004 patent on the 
sole ground that the claims to nucleotide sequences were invalid 
because they failed to satisfy the manner of manufacture requirement. 
Cancer Voices is a non-profit association, and Yvonne D’Arcy is a breast 
cancer sufferer. Although Cancer Voices became unincorporated during 
the course of proceedings, Ms D’Arcy was able to continue her case all 
the way to the High Court. Figure 1 shows a timeline of the case history. 
These points are elaborated below. 
                                                           
45  Dianne Nicol and John Liddicoat, ‘Do Patents Impede the Provision of Genetic Tests 
in Australia?’ (2013) 37(3) Australian Health Review 281. 
46  Genetic Technologies Ltd, ‘A Report to Shareholders’ (Annual Report, 9 July 2003) 1. 
47  Genetic Technologies Ltd, ‘New Position re BRCA Testing’ (Press Release, 2 
December 2008) 1. 
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Figure 1: The timeline of the D’Arcy litigation 
On 15th February 2013, the claims in issue were upheld at the first 
instance by Justice Nicholas.48 The key aspect of Nicholas J’s decision was 
that ‘[i]solated nucleic acid is the product of human intervention 
involving the extraction and purification of the nucleic acid found in the 
cell’.49 In essence, then, for Nicholas J the simple act of isolation of 
nucleotide sequences from a cell was enough to satisfy the ‘artificially 
created state of affairs’ component of the test in NRDC.50 The NRDC test 
requires both that the claimed subject matter (in that case a process of 
ridding weeds from crop fields) produces an artificially created state of 
affairs, and that it belongs to the useful rather than fine arts – that it is in 
the field of economic endeavour.51 The second limb was not in issue in 
the D’Arcy case.52  
On 15th September 2014, Chief Justice Allsop and Justices Dowsett, 
Kenny, Bennett and Middleton of the Full Federal Court upheld Justice 
Nicholas’ first instance decision.53 However, their reasoning was 
somewhat more nuanced. For their Honours, there was more to the 
invention than the simple removal of a nucleotide sequence from the 
inside of a cell. Their Honours held that ‘the claimed product is not the 
same as the naturally occurring product. There are structural differences 
but, more importantly, there are functional differences because of 
isolation’.54 In concluding, their Honours emphasised that the case is not 
                                                           
48  Cancer Voices Australia v Myriad Genetics Inc (2013) 99 IPR 567; [2013] FCA 65. 
49  Ibid [104]. 
50  NRDC (1959) 102 CLR 252. 
51  Ibid 277. 
52  D’Arcy v Myriad Genetics Inc (2014) 224 FCR 479, 510 [172]. 
53  Ibid. 
54  Ibid 517 [212]. 
The D’Arcy Decision and its Broader Impact 
 17 
about the wisdom of the patent system, nor the policy, moral and social 
reasons for excluding nucleotide sequences from patenting.55 Rather, it 
is about the law, and whether the principles articulated in NRDC apply. 
The first of five key features of the subject matter of the claim illustrates 
the essence of the core patent claim that led to their decision to uphold 
validity: ‘It is to a compound; a nucleic acid.  It is not a claim to 
information’.56 
On 13th February 2015, special leave was granted to appeal to the High 
Court. 
3.4.2  The High Court decision 
As noted earlier in this occasional paper, the High Court unanimously 
allowed the appeal, holding that the invention claimed did not fall within 
the concept of a manner of manufacture. Here, some of the key aspects 
of the reasoning of the judges in D’Arcy are explored. There were three 
separate judgments: 
Plurality – French CJ, Kiefel, Bell and Keane JJ 
The D’Arcy case is notable because of the way in which the plurality in 
that case refocused attention on the precise nature of the reasoning in 
NRDC. While acknowledging that in many instances the two-limb test will 
be sufficient, the plurality held that in some circumstances where the 
claims do not fall within the established boundaries of patentable subject 
matter it is necessary to look to a range of other factors.57 In the context 
of nucleotide sequences, even if the two-limb test were to be applied in 
isolation, the plurality held that the ‘artificially created state of affairs’ 
requirement would not be satisfied because in substance the claims were 
to information.58 Ms D’Arcy submitted that none of the chemical, 
structural or functional differences play any part in the definition of the 
invention, which is essentially the information.59 Their Honours agreed 
and found that the information was not something ‘made’ or ‘artificially 
created’. 
In the circumstances, because claims to nucleotide sequences did not fit 
within established boundaries, ‘wider considerations than Myriad’s 
characterisation of them as an “artificially created state of affairs of 
                                                           
55  Ibid 516 [204]–[205]. 
56  Ibid 516–17 [210]. 
57  D’Arcy (2015) 258 CLR 334, 351 [28]. 
58  Ibid 372 [91]. 
59  Ibid 371–2 [90]. 
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economic utility” come into play’.60 The plurality then propounded four 
additional factors that apply when a new class of claim involves a 
significant new application or extension of the concept. In summary, 
these are:  
3. whether patentability would be consistent with the purposes 
of the Act and, in particular: 
3.1 whether the invention as claimed, if patentable under s 
18(1)(a) could give rise to a large new field of monopoly 
protection with potentially negative effects on innovation; 
3.2 whether the invention as claimed if patentable under s 
18(1)(a) could, because of the content of the claims, have a 
chilling effect on activities beyond those formally the subject 
of the exclusive rights granted to the patentee;  
3.3 whether to accord patentability to the invention as 
claimed would involve the court in assessing important and 
conflicting public and private interests and purposes;  
4. whether to accord patentability to the invention as claimed 
would enhance or detract from the coherence of the law 
relating to inherent patentability; 
5. relevance to Australia’s place in the international community 
of nations:  
5.1 Australia’s obligations under international law; 
5.2 the patent laws of other countries; and 
6. whether to accord patentability to the class of invention as 
claimed would involve law-making of a kind which should be 
done by legislature.61 
Of these factors, the judges stated that factors 3, 4 and 6 are most 
important. Particularly persuasive to the judges was the odd 
consequence that if the claims are properly the subject of a patent, the 
patent could be infringed without the infringer being aware of that fact. 
That consequence coupled with the very large size of the relevant class 
of isolated nucleotide sequences (or nuclei acids as their Honours 
                                                           
60  Ibid 350 [27]. 
61  Ibid. 
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referred to them), raised the risk of a ‘chilling effect upon legitimate 
innovative activity outside the formal boundaries of the monopoly.’62 
Gageler and Nettle JJ 
Justices Gageler and Nettle focused more on the consideration of 
inventiveness in their judgment, noting that the process of isolating 
nucleotide sequences from the cell is a matter of longstanding practice.63 
Their Honours were of the view that, although the isolation of the 
nucleotide sequence comprising the BRCA1 gene is a man-made process, 
it does not involve any element of inventiveness. It is no more than the 
application of a well-known diagnostic technique to a known purpose of 
examining fragments of human DNA. On this basis, they found that the 
invention claimed makes no contribution to the manufacture of the 
substance.64 
Gordon J 
Justice Gordon found that the interrelationship between the isolation of 
the nucleotide sequence and the identification of the characteristic 
demonstrates why claim 1 is not a claim to a patentable product.65 
According to her Honour this was the case for a number of reasons, 
including that: the claim is to multiple products, not a single product; 
Myriad cannot identify the boundaries of the claim by reference to the 
chemical composition of the product; Myriad did not create, make or 
alter the code; there is no idea, concept or principle embodied in a 
manner of new manufacture; and the claim is too broad.  
 
3.5 IP AUSTRALIA PRACTICE NOTE 
Following the High Court’s judgment on 16 October 2015, IP Australia 
issued a draft Examination Practice for public consultation.66 Following 
completion of the consultation process, changes to the Manual of 
                                                           
62  Ibid 372 [93]. 
63  Ibid 393 [157]. 
64  Ibid 392 [155]. 
65  Ibid 409 [230]. 
66  ‘Commissioner’s Proposed Revised Examination Practice for Consultation 16 
October 2015 to 6 November 2015’ (Practice Note, IP Australia, 16 October 2016) 
<https://www.ipaustralia.gov.au/sites/g/files/net856/f/20151208_proposed_practi
ce_note_consultation.pdf>. 
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Practice and Procedure were made on 11 January 2016.67 The Practice 
Note affirms that isolated naturally occurring nucleotide sequences are 
excluded from patentability. As well as these, cDNA and synthetic 
nucleotide sequences, probes and primers, and isolated 
interfering/inhibitory nucleotide sequences that merely replicate genetic 
information of a naturally occurring organism are also excluded. 
The Practice Note states that in general the law is to be applied on a case 
by case basis taking into account the principles and approach taken by 
the High Court. First, for manner of manufacture, consideration needs to 
be given to the extent to which the claimed invention in substance falls 
within established categories of eligible subject matter (to which the 
principles of NRDC are relevant). The Note further clarifies that 
recombinant or isolated proteins, pharmaceuticals and other chemical 
substances, methods of treatment, methods of applying herbicides, and 
applications of computer technology are established categories against 
which NRDC principles can be applied. It is only when there is a new ‘class 
of claim’ that the additional factors set down by the plurality in D’Arcy 
need to be considered and, according to the Practice Note, this is a task 
for the Federal Court. 
 
3.6 AUSTRALIAN PATENT OFFICE DECISIONS CONSIDERING THE 
NUCLEOTIDE SEQUENCE EXCLUSION 
Recent decisions of the Australian Patent Office are starting to provide 
some indication of the impact of D’Arcy on the validity of patent claims. 
The first such case was Cargill Incorporated v Dow Agro Sciences LLC,68 
where the claimed invention was aimed at reducing saturated fatty acids 
in food to meet plant oil requirements for low saturates or no saturates 
labels in the US. The specification describes the process of fatty acid 
synthesis in oil and seeds. The delegate found that the substance of the 
claim was the genetic information in the nucleotide sequence, in line 
with D’Arcy. However, the delegate distinguished the claim from D’Arcy 
because the inventors had codon-optimised the naturally occurring 
fungal sequence, which changed the genetic information and 
                                                           
67  ‘2.9.2.6 Nucleic Acids and Genetic Information’ (Manual of Practice and Procedure, 
Australian Patent Office, 1 August 2017) 
<http://manuals.ipaustralia.gov.au/patents/adaptive_patents_manual/index.htm#t
=national%2Fpatentable%2F2.9.2.6_Nucleic_acids_and_genetic_information.htm>. 
68  Cargill Incorporated v Dow Agro Sciences LLC (2016) 123 IPR 300 (‘Cargill’). 
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distinguished the optimised sequence from its natural form.69 Thus, as a 
matter of legal interpretation, the delegate found that D’Arcy did not 
apply because this subject matter was not near the boundaries of 
patentability.70 
Another opportunity to consider the D’Arcy holding arose in Arrowhead 
Research Corporation, where the invention related ‘to the field of 
interfering RNA compositions for silencing spleen tyrosine kinase (syk) 
and for the treatment of Syk-related inflammatory condition’.71 The 
delegate found that the inventive contribution resided in the 
identification of specific target sequences, and that the target sequences 
themselves were crucial to the invention. However, the delegate 
concluded that while the arrangement of nucleotides or genetic 
information conveyed by the interfering RNA (‘iRNA’) incorporated in the 
RISC complex was an important element of the claimed invention, the 
manner in which the invention worked was not solely dependent on the 
sequence of nucleotides in the iRNA.72 The delegate considered the 
inventive contribution of the claimed invention and manner in which the 
invention worked, and on balance found that the factors supported the 
proposition that the substance of the invention was a pharmaceutical 
composition rather than genetic information. 
In Sun Pharmaceuticals v Tasmanian Alkaloids,73 the relevant patent 
claimed the mutagenesis of poppy seeds and screening of progeny plants 
to produce poppies with a higher output of codeine (over other 
alkaloids). The Patent Office delegate found no evidence that a mutation 
producing levels of codeine in line with those claimed in the patent, had 
or would be naturally occurring. Hence, there was no ground to oppose 
the patent on the basis that the subject matter was naturally occurring 
(as it was found to be in D’Arcy).74   
                                                           
69  Ibid 309 [41]. Codon optimisation involves switching rare codons [the set of three 
nucleotides that code for a particular amino acid] with more common codons that 
code for the same amino acid, thereby increasing the efficiency of protein 
expression.  
70  Ibid 310 [47]. 
71  Arrowhead Research Corporation [2016] APO 70 (13 October 2016) [5]. 
72  Ibid [13]. 
73  Sun Pharmaceuticals Industries (Australia) Pty Ltd v Tasmanian Alkaloids Pty Ltd 
[2018] APO 7 (31 January 2018). 
74  Ibid [69]–[71]. 
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In CSIRO v BASF Plant Science GmbH, the delegate considered two claims 
where manner of manufacture was an issue post D’Arcy.75 The claimed 
process uses molecular biology to take nucleotide sequences for the 
enzymes responsible for the production of long chain polyunsaturated 
fatty acids (‘LCPUFAS’) from lower species, and express them in the seed 
of the transgenic plant. This is useful to increase fatty acids, particularly 
in food. The delegate found that the substance of claim 19 and 
dependent claims was the genetic information embodied in the 
recombinant nucleic acid molecule which encodes the desaturase and 
elongase enzymes and includes associated regulatory sequences.76 The 
delegate found that the combination of enzyme-encoding nucleotide 
sequences and associated regulatory sequences specified in claim 19 
would not necessarily exist naturally in one nucleic acid molecule in any 
single organism, concluding that the claimed recombinant nucleic acid 
molecule had been made by human action.77 Further, claim 26 was 
directed towards an isolated nucleotide sequence which encoded a 
polypeptide that, BASF submitted, had been codon optimised. The 
delegate found that the sequence had been altered from one that occurs 
naturally in an alga so that it could be expressed in oil crop plants. 78 On 
this basis it satisfied the manner of manufacture requirement. 
These cases illustrate that, provided that there is a convincing argument 
to show that what is claimed is genetic information that has been altered 
from the state in which it naturally occurs, and the alteration is material 
to the invention, the manner of manufacture requirement will be 
satisfied in accordance with the D’Arcy holding. It should be noted that 
claims relating to methods of using nucleotide sequences are unaffected 
by the D’Arcy decision, provided that they: (a) do not amount to a claim 
to the nucleotide sequence itself; or (b) do not otherwise invoke adverse 
consideration of the factors propounded by the plurality in D’Arcy. In 
respect of point (a), in Commonwealth Scientific & Industrial Research 
Organisation v Agriculture Victoria Services Pty Limited,79 the delegate 
found that the claimed method related to a technological problem, in 
that it pertained to artificial selection and breeding of animals and 
                                                           
75  Commonwealth Scientific & Industrial Research Organisation v BASF Plant Science 
GmbH (2016) 124 IPR 406; [2016] APO 83 (23 November 2016). 
76  Ibid 415 [55]. 
77  Ibid 416 [58]. 
78  Ibid 416 [66]. 
79  Commonwealth Scientific & Industrial Research Organisation v Agriculture Victoria 
Services Pty Limited (2016) 121 IPR 468; [2016] APO 32 (3 June 2016). 
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plants.80 Method claims are considered further later in this occasional 
paper. 
Another Patents Office decision that warrants mention is Meat & 
Livestock Australia Limited and Dairy Australia Limited v Cargill, Inc.81 In 
that case, the invention related to methods utilising a high density, single 
nucleotide polymorphism map of the bovine genome. The high density 
map provided a resource for defining variation in the bovine genome and 
provided a means to link nucleotide sequences to gene traits. Claim 13, 
claiming ‘an isolated polynucleotide identified according to the method 
of claim 8’, was the subject of particular scrutiny in this case. Both parties 
filed further written submissions regarding the relevance of D’Arcy to this 
claim. The delegate found that claim 13 was ambiguous.82 She 
commented that if the applicant’s intention was to claim the isolated 
polynucleotides harbouring any of the naturally occurring sequences, 
this would amount to genetic information which had not been made. If 
this were the case, the isolated bovine polynucleotides claimed in claim 
13 would not satisfy the manner of manufacture requirement. However, 
the delegate rejected the opposition on all grounds except for the issue 
of clarity of claim 13, which she stated could be rectified by 
amendment. The decision of the delegate was appealed to the Federal 
Court of Australia. The judge in that case, Justice Beach, undertook a 
broad analysis, not only considering the holding in D’Arcy relating to 
nucleotide sequence claims, but also the plurality factors and the 
consequences for method claims. Justice Beach’s decision is considered 
in detail later in this occasional paper.  Before that, some of the earlier 
Federal Court musings on D’Arcy are considered.  
 
3.7 FEDERAL COURT DECISIONS CONSIDERING THE BROADER 
ASPECTS OF THE D’ARCY DECISION 
In recent Federal Court decisions, the Court has shown some reluctance 
to engage with the factorial approach set out by the High Court in D’Arcy. 
Commissioner of Patents v RPL Central was the first appellate decision 
                                                           
80  Ibid 481 [90]. 
81  Meat & Livestock Australia Limited v Cargill, Inc [2016] APO 26 (6 May 2016). 
82  Ibid [129].  
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where patentable subject matter was at issue post-D’Arcy.83 Justices 
Kenny, Bennett and Nicholas found that the implemented business 
method claim in suit did not reach the D’Arcy threshold requirement of 
‘a new class of claim involving a significant extension of the concept of 
manner of manufacture’ and thus the D’Arcy factors did not need to be 
considered.84 In the first instance decision in Gilead Sciences Pty Ltd v 
Idenix Pharmaceuticals LLC, Justice Jagot similarly found that the claims 
in suit, comprising chemical and pharmaceutical compounds, did not fall 
into a new class of claim and therefore did not require consideration of 
the D’Arcy factors (which her Honour noted are questions of policy).85 
Some commentators have asserted that the fact that the judges in these 
cases have not applied the D’Arcy factors illustrates that D’Arcy has 
increased uncertainty in patent law.86 This uncertainty stems from the 
concern that the lower courts may adopt an ‘extended and strained 
interpretation of D’Arcy in order to avoid invoking and subsequently 
applying the new factors’.87 Tanya Obranovich comments further that the 
D’Arcy decision has changed the law as it stood for 56 years and that it 
has reinterpreted the central principle upon which the determination of 
patent eligibility has been understood to be based.88 Her concern is that 
this has introduced uncertainty across a significantly wider scope of 
technologies than nucleotide sequences. Some law firms have also 
commented in their news bulletins that this case may cause more 
uncertainty for them.89 
                                                           
83  Commissioner of Patents v RPL Central Pty Ltd (2015) 238 FCR 27; [2015] FCAFC 177 
(15 December 2015).  
84  Ibid 54 [119].  
85  Gilead Sciences Pty Ltd v Idenix Pharmaceuticals LLC (2016) 117 IPR 252; [2016] FCA 
169 (2 March 2016). 
86  William Bartlett, ‘D’Arcy v Myriad Genetics Inc [2015] HCA 35: The Plurality’s New 
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Rebekah Gay and Tom Gumley also express some concern about the 
impact of the judgment of Gageler and Nettle JJ. As noted earlier in this 
occasional paper, while their Honours accepted that isolated nucleotide 
sequences are the products of human action, they rejected their 
patentability on the basis that they do not meet a threshold level of 
inventiveness.90 This inventiveness threshold was articulated in the 
earlier High Court case of NV Philips Gloeilampenfabrieken v Mirabella 
International Pty Ltd (‘Philips’) with regard to inventive step.91 However, 
the uncertainty that this concept was thought to introduce led to a later 
High Court decision in Lockwood v Doric rejecting any notion that Philips 
introduced a broad threshold test.92 Concern that the judgment of 
Gageler and Nettle JJ might lead to the re-introduction of this threshold 
test may be warranted. Post-D’Arcy, this argument was run by the 
applicant in Merial New Zealand v Jurox on the basis that the synergy of 
anthelmintics was neither new nor inventive.93 However, this argument 
could not be sustained on the facts and the delegate held that the claims 
were to a valid manner of manufacture. 
 
3.8 THE FEDERAL COURT DECISION IN MEAT AND LIVESTOCK 
AUSTRALIA V CARGILL 
A further opportunity for the Federal Court to scrutinise the D’Arcy 
decision, including both the breadth of the nucleotide sequence holding 
and the applicability of the factorial approach, arose in Meat & Livestock 
Australia Limited and Dairy Australia Limited v Cargill, Inc.94 As noted 
earlier in this occasional paper, the claims in issue related primarily to 
methods of using single nucleotide polymorphisms to link nucleotide 
sequences to gene traits. As such, Beach J was given the opportunity to 
                                                           
(16 October 2015) Corrs Chambers Westgarth 
<http://www.corrs.com.au/publications/corrs-in-brief/a-myriad-of-considerations-
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92  Lockwood Security Products Pty Ltd v Doric Products Pty Ltd [No 2] (2007) 235 CLR 
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93  Merial New Zealand Ltd v Jurox Pty Ltd [2017] APO 5.  
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consider what extra inventiveness is needed when what is claimed is a 
method of using excluded subject matter.  
In relation to the method claims, Justice Beach distinguished D’Arcy 
primarily on the basis that the claims were not purely to naturally 
occurring genetic information.95 His Honour considered the claims to be 
‘within the plain vanilla concept of manner of manufacture as outlined in 
NRDC and [D’Arcy] rather than a new class of claim’.96 Taking a sample 
and analysing the sample to identify single nucleotide polymorphisms 
associated with particular traits of interest was sufficient, in his Honour’s 
view, to give rise to an artificially created state of affairs.97  Justice Beach 
then went on to consider how the D’Arcy factors might apply, rejecting 
an assertion that upholding patentability would render the decision 
inconsistent with D’Arcy. His Honour restated his conclusion that the 
claims in issue were to methods applying information rather than to 
information per se.98 Further he found no lack of coherency with foreign 
law, and rejected an assertion that the ‘exorbitant’ breadth of the claims 
would likely have a substantial chilling effect on innovation.99 On this 
point, he did find that that the claims were too broad, lacked clarity and 
were poorly defined, and instructed the parties to amend the patent 
application.100  
Justice Beach also considered two product claims, one to an isolated DNA 
sequence (claim 13) and another to a cloned bovine (claim 11), both 
resulting from methods claimed in the patent. The sequence claim was 
rejected, as it fell within the bar created by D’Arcy.101 In contrast, Justice 
Beach found the claim to the cloned animal to be patentable subject 
matter, in marked contrast to the decision of the US Federal Circuit in re 
Roslin Institute (Edinburgh).102 The basis for his decision was that:  
the cloned cow in one sense is the same as that which it clones. 
MLA says superficially that it is ‘mere genetic information on a 
grander scale’ and accordingly Myriad is directly applicable. 
The submission has a superficial allure, but I reject it. An 
artificial object of economic significance is produced for its own 
                                                           
95  Ibid 205–7 [425]–[433]. 
96  Ibid 206 [428]. 
97  Ibid 211 [455]. 
98  Ibid 216 [487]. 
99  Ibid 218 [496] 
100  Ibid 178–9 [265]–[266], 219 [500]. 
101  Ibid 202 [409], 215 [482]. 
102  In re Roslin Institute (Edinburgh), 750 F 3d 1333 (Fed Cir, 2014). 
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sake, not merely as a receptacle for its informational 
content.103 
Justice Beach’s comment illustrates the divergence in approaches 
between the US and Australia. This case is discussed further in Chapter 
8. 
                                                           
103  Meat & Livestock Australia Limited v Cargill, Inc (2018) 354 ALR 95; [2018] FCA 51 
[470]. 
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CHAPTER 4 
THE GENETIC DIAGNOSTIC TESTING INDUSTRY IN 
AUSTRALIA  
 
4.1 GENETIC DIAGNOSTIC TESTING PROVIDERS 
As a first step in analysing the impact of nucleotide sequence and method 
patent claims on consumer access to and pricing of genetic diagnostic 
testing, it is necessary to have some understanding of the industry itself. 
There is some diversity in the types of organisations operating in this 
space. Traditionally, genetic testing has been performed by public 
pathology labs, either connected with or independent of public hospitals. 
Over time, a private industry has emerged. It seems likely that the private 
sector will expand as the demand for genetic diagnostic testing grows 
and as new technologies change the ways in which genetic testing 
services are delivered. For example, next generation sequencing 
machines, though expensive in themselves, require much less lab 
infrastructure than traditional testing methods. This means that in the 
future, once a lab has invested in sequencing machines it is relatively easy 
in financial terms to start to offer genetic diagnostic testing services. 
However, there is an increasing regulatory burden on providers, which 
may deter some market entrants. 
It is surprisingly difficult to get a clear picture of the constituents of the 
genetic diagnostic testing industry and the development of the industry 
over time in Australia. One reason is that in the past the regulation of the 
industry was decidedly ‘light touch’. The National Association of Testing 
Authorities (‘NATA’) was established many years ago, in 1947 and was 
formally recognised by the federal government as Australia's national 
provider of lab accreditation service in 1988.104 However, there was no 
mandatory requirement for labs offering genetic diagnostic testing 
services to be accredited by NATA unless they sought reimbursement for 
tests from the Medicare Benefits Scheme (‘MBS’).  
The role of the MBS in reimbursement for the cost of genetic diagnostic 
testing is discussed further below, but for now it is necessary to point out 
that because so few tests are listed on the MBS, providers could in the 
                                                           
104 National Association of Testing Authorities, Australia, Our History (2018) 
<https://www.nata.com.au/about-nata/our-history>. 
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past offer a wide range of tests without being NATA accredited. As such, 
there was no central clearing house to record participants in the industry, 
what tests they offered, how many tests they performed and how they 
priced those tests. The Royal College of Pathologists of Australia (‘RCPA’) 
has undertaken valuable work in this area. The RCPA undertook two 
surveys of genetic testing providers in 2006 and 2011. The 2006 survey 
involved responses from 52 out of 56 labs that were identified as 
providing medical genetic testing in Australia.105 The 2011 survey 
involved responses from 39 of 42 NATA accredited labs that provided 
medical genetic testing during that year.106 One key point from the 2011 
survey is that it showed a 2.8 fold increase in volumes of tests from 2006. 
We understand that the RCPA was commissioned to undertake another 
survey in 2017. 
As alluded to above, in parallel with this increase in volume of genetic 
testing in Australia, more rigorous regulatory requirements have been 
imposed on the industry. Although general laws of negligence, consumer 
protection and the like applied to the genetic diagnostic testing industry, 
there was no comprehensive regulatory framework until 2002. Pursuant 
to the Therapeutic Goods Amendment (Medical Devices) Regulation 2002 
(Cth) diagnostic testing kits were considered to be in vitro devices 
(‘IVDs’), requiring registration on the Australian Register of Therapeutic 
Goods. However, the vast majority of genetic tests were still considered 
to be exempt from the Register. It was not until 2010 that a 
comprehensive regime was introduced requiring registration of 
diagnostic genetic tests as IVDs. The requirement for registration applies 
to both over-the-counter genetic diagnostic test kits and in-house (or lab-
based) genetic diagnostics.107 One of the conditions of registration is that 
the lab undertaking the testing be NATA accredited. One consequence of 
this strengthening of the regulatory requirements on genetic diagnostic 
testing labs is that it is easier to get a clearer picture of the extent of the 
industry now than in the past through the NATA website, but only insofar 
as the testing is therapeutic.  
                                                           
105  Royal College of Pathologists, ‘Report of the RCPA Genetic Testing Survey 2006’ 
(Report, 31 July 2009) 7. 
106  Royal College of Pathologists, ‘Report of the RCPA Genetic Testing Survey 2011’ 
(Report, December 2012) <https://www.rcpa.edu.au/Library/Practising-
Pathology/RCPA-Genetic-Testing/Docs/RCPA-Genetic-Testing-Survey-Report.aspx>. 
107 Therapeutic Goods Administration, Overview of the Regulatory Framework for In-
vitro Diagnostic Medical Devices (6 July 2011) <https://www.tga.gov.au/overview-
regulatory-framework-vitro-diagnostic-medical-devices>; See also Dianne Nicol and 
Meredith Hagger, ‘Direct To Consumer Genetic Testing – A Regulatory Nightmare?’ 
(2013) 198 Medical Journal of Australia 501. 
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NATA lists 45 labs in its genetic testing facility webpages. In Table 3, the 
labs have been separated out by type. We suspect that the webpages 
may not be fully up to date as we understand that other foreign entities 
may have entered the Australian market.  Nevertheless, this gives us a 
reasonably accurate picture of the current Australian genetic diagnostic 
testing industry. We note that that the Human Genetics Society of 
Australasia has also in the past operated a useful website listing providers 
of genetic diagnostic testing services, but this website has now been 
discontinued and a link is provided that directs users to the NATA 
website. We have made use of this website in our earlier research. 
Table 3 clearly shows that the bulk of genetic testing facilities are located 
in pathology labs connected with public hospitals or independent of 
them. There is a geographical spread of these facilities across Australia, 
with the bulk in New South Wales and Victoria. Some, but not all of these 
labs offer BRCA testing. Some of the major research institutes and 
universities also offer genetic diagnostic testing. In particular, the Garvan 
Institute and the Peter MacCallum Institute offer a diverse array of tests. 
Peter MacCallum has, for many years, offered BRCA testing.  
With regard to the private sector, it should be noted that Genomic 
Diagnostics took over GTG several years ago. As might be expected given 
this connection, Genomic Diagnostics offers BRCA testing. Previously, 
another major private provider of genetic testing and other pathology 
services in Australia was Healthscope. It is our understanding that the 
pathology component of Healthscope’s business was taken over by 
Australian Clinical Laboratories in mid-2015. It appears that genetic 
diagnostic testing is only a small component of this company’s business, 
and only in the fields of haematology and oncology.108 It does not offer 
BRCA testing. These developments illustrate the fluidity of the private 
pathology industry. 
                                                           
108 Australian Clinical Labs, Haemotology and Oncology (2017) 
<https://www.clinicallabs.com.au/doctor/specialists-services/haematology-
oncology/>. 
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Another vital component of the genetic diagnostic testing industry is the 
clinical genetic testing service. This service provides genetic counselling 
to individuals and their families, and often is the main point of entry into 
the public system. Most states and territories have a single service, 
although New South Wales and Victoria have multiple separate services. 
The service is staffed by clinical geneticists, who are medical specialists, 
and genetic counsellors, who are allied health professionals. General 
practitioners and specialists are responsible for referral of their patients 
for diagnostic testing. The 2011 RCPA Report indicates that 54 per cent 
of labs reported operating under a formal or informal memorandum of 
understanding with a local clinical genetics service.109  
Direct to consumer genetic diagnostic testing is not permitted in 
Australia, although there are a number of Australian and foreign 
companies that offer a variety of direct to consumer genetic services. 
These include ancestry, paternity, diet and health-related (non-
therapeutic) tests. The question of how to regulate this sector of the 
industry is both topical and controversial, and is another area of research 
interest for us.110  
 
4.2 TYPES OF GENETIC DIAGNOSTIC TESTS AND VOLUME OF 
TESTING  
There is considerable overlap between labs in the types of tests they 
offer, although a number have expertise in specific conditions. Many of 
the hospitals and research institutes, for example, test for rare 
conditions. Some labs perform very specific tests (eg monogenetic 
disease, or heritable cancers). Others are more general and perform a 
broad range of tests, particularly within the public system. Many labs 
perform tests in-house using kits they have developed. In many other 
instances, commercial test kits are used, and in other cases testing is 
outsourced to labs within Australia or internationally.  
Decisions as to which tests particular providers perform are determined 
to some degree by their level of expertise, and which tests have 
historically been performed. It is probably fair to say that public providers 
perform the broadest range of tests, and testing for some conditions is 
                                                           
109  Royal College of Pathologists, ‘Report of the RCPA Genetic Testing Survey 2011’, 
above n 106, 4. 
110  See, for example, Nicol and Hagger, above n 107; Dianne Nicol et al, ‘Precision 
Medicine: Drowning in a Regulatory Soup?’ (2016) 3 Journal of Law and the 
Biosciences 281. 
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only available through clinical genetics services (this is especially the case 
with some familial cancers). Notwithstanding, the private labs perform a 
very large volume of tests. Although data on the number of tests 
performed per lab on an annual basis is not publicly available, the larger 
groups (eg Sonic Group, Primary Healthcare, the NSW Department of 
Health and the Victorian Department of Health) perform a sizeable 
proportion of tests. To give some indication of testing volume, the NSW 
Department of Health conducts in the vicinity of 80,000 – 100,000 tests 
per year. 
Recently, the volume of patients presenting for testing has increased 
dramatically. Interviewees from publicly-funded labs reported a sharp 
incline in the number of tests being performed from 2013, primarily as a 
result of the ‘Angelina effect’. Angelina Jolie’s publicisation of her 
prophylactic mastectomy and oophorectomy has raised awareness of 
diagnostic testing for inherited conditions. Interestingly, the Tasmanian 
Department of Health and Human Services reports a steady incline in 
consults for genetic diagnostic testing from around 800 requests per year 
(2011/12) to just under 1,400 per year (2014/15).111 A vast majority of 
requests relate to familial cancers, primarily breast cancer. An attempt 
to put a number on how many of the increased presenting cases had valid 
genetic predispositions illustrated that just seven per cent did not. In 
other words, publicisation of the availability of genetic diagnostic testing 
had unearthed many patients with genetic predispositions to develop 
familial cancers. One interviewee from a standalone public lab in Victoria 
stated that the rate of patients presenting for testing with no valid basis 
on which to suspect a BRCA mutation is also likely to be around seven per 
cent.  
Changes in testing technologies are also increasing the amount of testing 
being performed. Testing methods are rapidly evolving. Traditionally, 
sequencing technologies have involved single gene and multiple gene 
(gene panel) sequencing methodologies using chemical-based, Sanger 
sequencing techniques. These testing methods provide a result that 
indicates whether a specific gene has particular variations, and are useful 
where looking for a known mutation causative of a disease. The 
techniques are well-established and well validated. Their limitations in 
testing for more complex genetic conditions has resulted in a move to 
next-generation sequencing, including whole exome and whole genome 
sequencing. While many Australian labs still use single-gene and panel-
based tests (with one interviewee referring to them as the ‘gold 
standard’), many interviewees reported they had moved to employing 
                                                           
111 Tasmanian Clinical Genetics Service, Annual Report (2014–15). 
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exome sequencing. The basis for this move is the vast amount of data 
these testing technologies produce, which is likely to afford a more 
holistic interpretation of test results.  
This change in technology presents challenges: the capital investment 
required to maintain abreast with the newest technologies is substantial. 
The pace at which the technology is moving is rapid. Machines being used 
today (for example, Illumina’s next generation sequencers employed by 
many of our interviewees), may well be obsolete in five years’ time. This 
cost of the provision of genetic diagnostic testing is a significant one. It 
presents issues for industry participants across both the public and 
private sectors. All but one of our clinical interviewees across both public 
and private labs indicated that their labs had moved to next generation 
sequencing techniques where appropriate, with the result that their labs 
employed both traditional and next generation sequencing methods. 
 
4.3 COSTING AND REMUNERATION FOR GENETIC DIAGNOSTIC 
TESTING  
Cost has always been a major factor in debates surrounding the 
accessibility of genetic diagnostic testing. The funding model for genetic 
diagnostic testing is surprisingly complex. Generally speaking, a vast 
majority of funding for healthcare emanates from federal funding, 
particularly through the MBS, which funds medical services (including 
services provided by GPs and specialists, diagnostic imaging, pathology 
and a host of other services), and the Pharmaceutical Benefits Scheme 
(‘PBS’).112 Genetic diagnostic testing is somewhat of an anomaly in this 
regard, in that few tests are listed on the MBS and the bulk of funding is 
provided through state government healthcare budgets. Data obtained 
by the RCPA in 2011 showed that reimbursement for medical genetic 
testing in Australia was provided by private patients (19.7 per cent), state 
governments (39.2 per cent) and federal sources (34.1 per cent).113 In a 
majority of instances, testing on interstate samples was reimbursed by 
the referring lab (73.2 per cent).114 
                                                           
112  Australian Bureau of Statistics, Health Care Delivery and Financing (24 May 2012) 
<http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/1301.0~2012~
Main%20Features~Health%20care%20delivery%20and%20financing~235>. 
113  Royal College of Pathologists of Australasia, ‘Report of the RCPA Genetic Testing 
Survey 2011’, above n 106, 21. 
114  Ibid. Patients were reimbursed in respect of 12 per cent of tests performed, while 
the testing lab covered the cost in 11.2 per cent of cases. 
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Most genetic diagnostic testing is performed by public providers, either 
through referrals from clinical genetic testing services or directly through 
referrals from specialists. Patients accessing diagnostic genetic testing 
through this route are not expected to make any payment. From time to 
time, patients present privately at public clinics without a referral from a 
clinician, usually on the basis that they do not meet the risk profile that 
would result in a referral. In these circumstances, they may be expected 
to cover the cost of their genetic test from their own pocket, although 
the public lab may choose not to bill the patient. Charges vary, depending 
on the type of test, with a range from less than fifty dollars up to more 
than a thousand dollars. Private insurers in Australia do not fund any 
genetic diagnostic tests. Private labs rely for their business on patients 
funding their own tests, reimbursement from the MBS for listed tests, or 
alternatively, on payment by public labs out of their grant funding 
allocated by the state. Public labs do often make requests for testing to 
be undertaken by private labs, particularly for rare diseases.  
We (Nicol and Nielsen) conducted our first study of patenting and 
licensing practices in the Australian medical biotechnology industry in 
2002–2003.115 The study included a survey of managers of genetic 
diagnostic testing labs. Printed surveys were mailed out to the labs 
offering genetic diagnostic testing listed on the Human Genetic Society 
of Australia’s website in 2002. The survey included questions on the cost 
of tests, the results of which are broadly summarised in Table 4. This 
gives a rough indication of the range of fees, which we have separated 
out into four categories, illustrating the variability in fee structures. A 
more fine-grained analysis of the fees charged for particular tests in 
2002–2003 compared with current fees is presented in Chapter 5 of this 
occasional paper. 
 
 
 
 
 
 
                                                           
115  Dianne Nicol and Jane Nielsen, ‘Patents and Medical Biotechnology: An Empirical 
Analysis of Issues Facing the Australian Industry’ (Occasional Paper No 6, Centre for 
Law and Genetics, 2003). 
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Table 4: Cost of tests: 2002–2003 Study  
 Number of respondents 
Percentage of 
respondents Fee range 
Free 4 13  
Free to in-state 
patients, fee to 
others 
5 16 $200 - $1500 
Some covered by 
MBS, fee for others 6 19 $35 - $1800 
Fee based 6 19 $50 - $1950 
No answer 10 32  
 
The 2011 RCPA survey provides some further insight into the funding of 
genetic diagnostic tests. The survey asked providers how tests performed 
in their labs during 2011 were funded. Results showed that 
approximately 40 per cent of assays undertaken in public labs were 
funded by the state/territory that performed the test, with the 
remainder being funded federally (34.1 per cent) or by the patient (19.7 
per cent).116 Approximately three-quarters of assays performed on 
interstate samples were funded by the referring lab.117 The costs of 11 
per cent of assays performed on samples from outside of the state were 
absorbed by the lab performing the testing,118 possibly reflecting the fact 
that these tests were conducted for private patients who often find it 
difficult to cover the cost of testing. 
The 2011 RCPA Report also considered the quantity of samples sent 
overseas and reported that in comparison with 2006, the proportion had 
increased.119 However, the figure remained a small fraction of overall 
tests performed (2,744 assays requested from overseas labs,120 579,742 
                                                           
116  Royal College of Pathologists, ‘Report of the RCPA Genetic Testing Survey 2011’, 
above n 106, 21. 
117  Ibid 4. 
118 Ibid 21. 
119  Ibid 28. 
120  Ibid 26. 
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assays performed nationally121). Samples were generally sent for 
diagnostic purposes and constituted molecular genetics assays.122  
Pricing in public labs is generally calculated on a cost-recovery basis. 
Health care providers manage test pricing on an individual level, within 
their allocated budget. The cost of testing is driven by a significant 
number of factors, including:  
• the complexity of the genes involved; 
• sequencing equipment capital, operational and maintenance 
costs;  
• the cost of testing materials (eg assays, reagents and commercial 
test kits); 
• the cost of interpretation of test results; 
• the cost of support services; and 
• significantly, the price tolerated by the market – the presence of 
competitors will be an important factor in cost determination.  
While cost recovery is also an important aspect of pricing for private 
providers, clearly pricing in this case incorporates some profit margin. 
The discrepancy between the market for public test providers and that 
for private providers presents private providers with some scope to 
charge more per test than prices that would be charged in the public 
system. 
Changing technologies was consistently reported to us as being the most 
significant factor affecting pricing. Both public and private providers have 
recently decreased test prices, because the pricing of Sanger sequencing 
methods has declined. As an example, the cost of doing a single gene 
assay was around $1,800 a decade ago.  That price has now decreased to 
$50-$800 (depending on the complexity of the gene involved). Whole 
exome sequencing was previously an expensive exercise but a dramatic 
fall in the price of conducting exome sequencing means that it will now 
cost around $1,000 to produce a whole exome sequence. The cost of 
interpretation is an additional and very significant cost, given the amount 
of data a whole exome sequence generates. But it does demonstrate the 
huge impact the price of technological advancement is having on pricing 
fluctuations within this industry. Having said this, one test provider 
                                                           
121  Ibid 13. 
122  Ibid 26. 
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stressed the continuing importance of Sanger sequencing methods in 
certain circumstances: 
[N]ext generation sequencing can be a sledgehammer to break 
a nut. Once you know a particular familial mutation, a simple 
sanger sequencing … saying do they carry this particular 
variant, is much more cost effective. 
There are further limits to what may be charged: recently the testing 
environment has become far more competitive, with a number of new 
US providers entering the market. In the case of these providers, testing 
is conducted offshore via an Australian clinician. According to two of our 
interviewees, this may be because overseas providers are more 
competitive or because clinicians are not aware that anyone in Australia 
provides that particular test. Providers in other countries are also 
impacting on the market – one interviewee mentioned the fact that 
companies in South Korea offer whole exome sequencing for $500-$600. 
While this was viewed as a positive factor by our interviewees from 
health departments, clinicians worried that the price competition may 
make it extremely difficult to maintain the standard of service currently 
being provided. In a previous section of this occasional paper, we 
discussed the fact that some state health departments are beginning to 
abandon the block funding model that has governed funding for the 
genetic testing sector. A move away from a system of block funding may 
also have the effect of encouraging price competition between providers, 
a fact that was noted by one interviewee, a senior health department 
official from a jurisdiction that had recently changed its funding model to 
attempt to achieve this outcome. 
 
4.4 STATE GOVERNMENT FUNDING FOR GENETIC DIAGNOSTIC 
TESTING 
Funding for genetic diagnostic testing at the state level has generally 
been in the form of block grants, though we understand that this 
situation is now changing, with more stringent requirements in some 
jurisdictions for labs to provide more detailed accounts of costs and 
volume of testing. Our interview data makes it clear that funding within 
state budgets for genetic diagnostic testing services is complex and 
involves a considerable amount of speculation. The budget allocated by 
each state health department is distributed between its clinical genetics 
service and labs – costing models are generally derived from historical 
and forecast data on test volumes and costs. Clinical genetics services 
and labs must work within their budgets. Public patients tested within 
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their home state generally receive free testing (covered by the budget of 
the lab doing the testing). Where testing is performed on samples from 
other states, reimbursement is generally sought from the health 
department/hospital budget of the patient’s home state. Tasmania, for 
example, sends a vast majority of its samples to Victoria for testing, given 
that there is very limited capacity for genetic testing in Tasmania. This is 
reflected in the 2011 RCPA Report.123 
Clinical genetics services do not automatically provide testing for all 
patients who request it. Prospective patients’ risk profiles are analysed 
for eligibility based on many factors including family history and health 
background. Samples provided by private patients (eg patients admitted 
as private patients in public hospitals or patients who do not meet the 
required risk profile for testing) may also be tested in publicly-funded 
labs where necessary: our interviewees from private companies 
indicated that they would send samples to public labs for testing where 
necessary. Public labs also send samples to private labs. This might occur 
where a public lab is too busy to conduct testing in a timely manner, or 
where a very quick turnaround time is required. One of our interviewees 
informed us that their state-based BRCA testing lab sometimes sent 
samples to GTG to be tested on these bases. In some cases, a publicly-
funded lab may be the only lab that tests for the particular condition. 
Generally, reimbursement is sought for tests performed for private 
patients, although we were made aware that there are often instances 
where this does not occur due to a perception that the patient would 
have difficulty covering the cost of the test. In these instances, the testing 
costs are absorbed by the state health care budget. 
One interviewee from a state health department explained the concept 
of block funding, a model which has prevailed in the area of genetic 
diagnostic testing. Block funding involves the provision of funding for a 
particular genetic test to one state-funded provider. This gives labs a 
virtual monopoly on testing in respect of specific genetic conditions. The 
Victorian health department has recently moved away from a system of 
block funding in order to encourage multiple labs to undertake testing 
for particular genetic conditions and to generate competition. One 
question that might arise here, however, is whether a reduction in 
economies of scale and expertise might mean a commensurate rise in the 
cost of providing testing. One matter that factors strongly into putting a 
price on testing is being able to optimise the use of equipment and 
personnel through high volume testing. Not surprisingly, some labs that 
                                                           
123  Royal College of Pathologists, ‘Report of the RCPA Genetic Testing Survey 2011’, 
above n 106, 13, 23. 
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have developed expertise in areas involving rare diseases remain the only 
labs to test for those conditions. Labs are more likely to move into 
broader testing practices in areas where testing demand is high, given 
that in some circumstances some further capital outlay might be 
required. The reality so far, however, is that labs remain likely to test in 
areas in which they have long-term expertise, so that the testing 
landscape in Victoria had not changed dramatically to date. For example, 
all of Victoria’s BRCA testing is still done by the Peter MacCallum Cancer 
Centre. 
 
4.5 MEDICARE BENEFITS SCHEDULE 
A low level of federal funding is provided for genetic diagnostic testing 
through the MBS. A very limited number of genetic tests are listed on the 
MBS for specific indications, including haemochromatosis, Fragile X 
syndrome, Factor V Leiden and some other inherited thrombophilias. In 
addition, various tests for chromosomal analysis are also available on the 
MBS. These include karyotyping and chromosomal microarrays for 
investigation of developmental delay.124  
Interestingly, the number of tests reimbursed per annum through the 
MBS did not alter significantly between 2006 and 2011.125 In 2011, labs 
reported the performance of 163,296 MBS-funded assays (excluding 
17,882 HLA-typing assays).126 The proportion of MBS-funded molecular 
genetic assays increased marginally from 24 per cent (in 2006) to 26 per 
cent (in 2011) of total assays performed.127 This federally funded testing 
comprised 60 per cent molecular genetic assays, 39 per cent cytogenetic 
assays and 1 per cent biochemical genetic assays. This is despite the 
addition of several new tests to the MBS,128 and despite the number of 
newly developed molecular diagnostic tests offered rising steeply during 
that period.129  
                                                           
124  Australian Government Department of Health, The November 2016 Medicare 
Benefits Schedule (7 November 2016) 
<http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Downloads
-201611>. 
125  Royal College of Pathologists, ‘Report of the RCPA Genetic Testing Survey 2011’, 
above n 106, 22. 
126  Ibid 21. 
127  Ibid 22. 
128  Ibid. 
129  See ibid 18. 
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Although an MBS listing merely shifts funding obligations from the state 
to the Commonwealth, the availability of an MBS funded test could result 
in increased demand by patients who do not meet current risk profiles 
for state-funded testing, but nonetheless desire testing. It would be 
prudent to maintain a watching brief to ascertain whether future RCPA 
reports indicate increased uptake of tests due to further additions to the 
MBS in the form of genetic diagnostic tests. Relevantly, the Medical 
Services Advisory Committee (‘MSAC’), which provides advice to the 
Australian Government on whether a new medical service should be 
publicly funded, is currently considering the addition of a number of new 
items related to genetic testing to the MBS.  
Two new items have been added since 1 November 2017, which provide 
reimbursement for testing for BRCA1 and BRCA2 mutations.130 The first 
provides BRCA testing for women who have been diagnosed with breast 
or ovarian cancer. The second permits family members of women with a 
positive test result to also undergo testing for the same mutation. The 
implications of these additions are discussed further in Chapter 6 of this 
occasional paper. The consensus view among our interviewees is that 
calculating an accurate amount for reimbursement via the MBS is 
incredibly difficult, and probably unrealistic given the time lag between 
MSAC making a determination on listing a particular item, and listing 
taking place. Technological developments soon render current price 
estimates obsolete. Our interview data indicates that even private 
providers rarely charge more than the scheduled fee where performing 
MBS-rebated tests. This is due to the fact that MBS-listed costs become 
the price the market will tolerate. Paradoxically, while the rebateable 
costs for conditions such as Fragile X and haemochromatosis ($86.15 and 
$31 respectively) are now viewed as being less than the cost of 
performing these tests, the cost for the current BRCA1 listing is `far more 
generous than the cost of actually performing the test’. Given that this 
test impacts on such a low proportion of patients with a BRCA1 mutation, 
the implications of this appear to be presently limited. A broader listing 
(as occurred in 2017) may well result in a spike in demand for BRCA 
testing from patients who have been diagnosed with breast or ovarian 
cancer, or who have a family history of these conditions. Increased 
demand would be partially practitioner-driven given that patients are 
unlikely to personally be aware of the MBS additions. Importantly, 
however, BRCA testing is now informing treatment to a far greater extent 
                                                           
130  Letter from Michael Ryan to Phillip Truskett AM, Royal Australasian College of 
Surgeons, 19 December 2016 <https://www.surgeons.org/media/24932828/new-
amended-mbs-listings.pdf>. 
Chapter 4 
 42 
than in the past, as noted by one interviewee from a state health 
department: 
BRCA testing can now inform treatment. Not just treatment 
with drugs but surgery. We know that some breast surgeons 
are sending their patients with a cancer diagnosis (for testing) 
which is not the model for family cancer centres. … We know 
that breast cancer surgeons are sending their diagnosed 
patients to our FCCs for BRCA testing to inform whether or not 
to do mastectomies versus lumpectomies. 
This interviewee reported a significant increase in demand for BRCA 
testing on the basis of this factor alone, and stated that this had put more 
pressure on the state funded genetics services funding the testing. 
One interviewee from a private testing lab commented that increasing 
the number of tests listed on the MBS could impact on the viability of the 
private testing industry. This is because private labs would be reliant on 
the typically low MBS rebates (which may not cover costs), whereas 
international competitors can charge any amount. This would affect their 
ability to compete with international labs. Another from a pathology lab 
based at a public hospital stated in the context of MBS rebates: 
Speaking to someone who was connected to the private sector, 
they were basically saying their genetic service loses money for 
them in terms of that. … In the public and in the private sector, 
genomics has to be cross-subsidised by a lot of other forms of 
testing. 
 In other words, this respondent’s view was there is not a lot of money to 
be made from performing MBS-listed tests. One interviewee from a 
private lab, however, argued for increased MBS listings in respect of 
genetic testing, stating that ‘[t]he smaller (private) pathology providers 
cannot survive on the diminishing returns that Medicare provides.’ 
Another interviewee from a private lab said that it is cost-effective to 
perform the simpler MBS-listed tests, although the margins are 
considerably less on the more complex tests. A general conclusion we 
were able to draw is that state-based health department employees are 
far more strongly in favour of increasing the number of MBS listings than 
representatives of privately funded labs. This is unsurprising given the 
structure and funding model inherent in the industry. For those in public 
labs, a change in their funding source would have little overall impact.   
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CHAPTER 5 
WHAT WE KNOW ALREADY ABOUT THE IMPACT OF 
NUCLEOTIDE SEQUENCE AND METHOD PATENT 
CLAIMS ON GENETIC DIAGNOSTIC TESTING 
 
5.1 THE CHO AND MERZ STUDIES 
Concerns about the potential for nucleotide sequence and other patents 
to impact negatively on the provision of genetic diagnostic tests were 
first raised in earnest in the academic literature by Mildred Cho, Jon Merz 
and their colleagues in the US in the early 2000s, in part in response to 
the action of Myriad in actively enforcing its BRCA-related patent rights. 
However, they found that these concerns about access to genetic 
diagnostic testing went far beyond BRCA. Their work demonstrated that 
a number of patent and licence holders were actively enforcing their 
patents against genetic test providers either by requiring licences 
containing objectionable terms, or by refusing to license.131 Problematic 
licence terms related to the cost of testing, the quantity of tests that 
could be performed, which labs the tests could be performed in, and 
whether further research to improve the quality and specificity of tests 
was permitted.  
Cho et al reported that a number of test providers ceased to perform a 
genetic test they had previously offered, while a number of others 
decided not to develop or perform a test because of patent 
considerations. In total, they identified 22 patents that were being 
actively enforced at the time, affecting 12 genetic tests.132 Those genetic 
tests related to common genetic disorders, including haemochromatosis, 
Fragile X syndrome, Duchenne muscular dystrophy and Huntington’s 
disease, and to more complex disorders such as Alzheimer’s disease and, 
of course, hereditary breast cancer.   
In 2003 we conducted searches of patent databases for equivalent 
Australian patents. These searches showed that three of these US 
                                                           
131  Jon F Merz et al, ‘Diagnostic Testing Fails the Test’ (2002) 415 Nature 577; Mildred K 
Cho et al, ‘Effect of Patents and Licenses on the Provision of Clinical Genetic Testing 
Services’ (2003) 5 Journal of Molecular Diagnostics 3. 
132  Cho et al, above n 131, Table 2. 
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patents had direct equivalents in Australia and four others were the 
subject of Australian patent applications (Table 5). Closely related 
Australian patents or patent applications (that is, having the same patent 
holder and subject matter) existed for most of the others. Only three had 
no direct or closely-related equivalents in Australia. As such, we 
predicted that the capacity existed at the time for a number of nucleotide 
sequence patents to be enforced against providers of genetic diagnostic 
services in Australia.  
We recently conducted further searches of the AusPat database to 
determine the current status of these patents and applications. As can 
be seen in the last column of Table 5, all granted Australian patents 
identified in our earlier study have now ceased or expired, and all 
applications have lapsed, save one application that appears to have been 
misidentified in our earlier study. This indicates that the threat of 
enforcement of these particular patents in Australia has now dissipated, 
in that they have suffered a ‘Darwinian fate’ as some of our Belgian 
colleagues have put it.133 This is not to say that there are no patents that 
have the capacity to impinge on the genetic diagnostic testing landscape, 
just that the particular Australian equivalents to patents identified by 
Cho, Merz and their colleagues no longer occupy this landscape. 
 
                                                           
133  Isabelle Huys, Gert Matthijs and Geertrui Van Overwalle, ‘The Fate and Future of 
Patents on Human Genes and Genetic Diagnostic Methods’ (2012) 13 Nature 
Reviews Genetics 441.  
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M
yotonic dystrophy 
US5955265 and 
US5977333 
M
IT and University of W
ales 
College of M
edicine 
 
AU199335059 
Lapsed 
Canavan disease 
US5679635 
M
iam
i Children’s H
ospital 
Research Institute 
AU199473207 
 
Lapsed 
Spino-cerebellar 
ataxia (SCA1, SCA2, 
SCA3, SCA6) 
US5834183 and 
US5741645 (SCA1) 
Regents of University of 
M
innesota 
No equivalent 
 
 
US6251589 (SCA2) 
SRL, Inc 
AU199664698 
 
Lapsed 
US5840491 (SCA3) 
Kakizuka, A 
No equivalent 
 
 
US5853995 (SCA6) 
Research Developm
ent 
Foundation 
AU735756 
 
Ceased 
Adenom
atous 
polyposis of the 
colon 
US5352775 
Johns Hopkins University 
 
AU199213669 
Lapsed 
Charcot-M
arie 
Tooth type 1A 
US5780223 
Baylor College of M
edicine 
 
AU199222265 
Lapsed 
US5691144 
Athena Diagnostics, Inc 
No equivalent 
 
 
Fragile X syndrom
e 
US6107025 
Baylor College of M
edicine 
AU199221854 
 
Lapsed 
H
untington’s 
disease 
US4666828 
The General Hospital Corp 
 
AU676001 and AU673575 
AU676001 – ceased 
AU673575 – ceased 
Factor V Leiden 
US5874256 
Rijks Universiteit 
AU690644 
 
Expired 
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5.2 THE NICOL-NIELSEN STUDY 
The 2002–2003 Nicol-Nielsen study of patenting and licensing practices 
in the Australian medical biotechnology industry was undertaken at the 
time when the studies undertaken by Cho and Merz in the US were 
garnering some public and academic attention in other countries, 
including Australia.138 It was also at a time when GTG was starting to 
assert its patent rights over its intron sequence analysis patents 
(colloquially known as ‘junk DNA’ patents),139 and when the strategic 
alliance between GTG and Myriad was first being made public. Not 
surprisingly, there was concern amongst providers of genetic testing 
services at the time that GTG could prevent them from offering BRCA1 
and BRCA2 testing. However, it was probably too early to observe any 
form of coordinated enforcement action on the part of GTG in respect of 
the BRCA patents for which it was the exclusive licensee. 
The survey of labs offering genetic diagnostic testing services, which was 
undertaken as part of the Nicol-Nielsen study, asked 61 questions about 
the lab, its clinical activity, research and patent activity, and 
collaborations. A total of 52 surveys were dispatched. Eighteen were 
returned (35 per cent response rate). These detailed surveys were 
supplemented by short telephone surveys conducted in March and April 
2003 asking six questions about the lab, the tests it performs, payment 
of licence fees and/or royalties, receipt of notifications from patent or 
licence holders, responses to notifications, and views on patents. The six 
questions were only asked if respondents indicated that they had not 
returned the written survey. Hence, we were reasonably confident that 
the telephone survey respondents did not overlap with the written 
survey respondents. There were thirteen responses to the telephone 
survey, yielding a total response rate of 60 per cent.  
One of the key questions for respondents was whether they were 
required to pay licence fees or make royalty payments to any patent 
holder in respect of any of the tests they performed. They were then 
asked to specify the nature and number of licences in the following 
categories: genetic test; reagents; PCR; other methods; and other. They 
were also asked to specify the method of payment (eg up front licence 
fee, royalty, both). The results are summarised in Table 6. Eleven 
respondent labs (35 per cent) reported that payments of licence fees 
and/or royalties were made, but almost all of these (9 out of 11) were 
                                                           
138  Nicol and Nielsen, above n 115. 
139  The early history of GTG’s actions is traced in Dianne Nicol, ‘Balancing Innovation 
and Access to Healthcare through the Patent System - An Australian Perspective’ 
(2005) 8 Community Genetics 228. 
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royalties paid to Roche Inc for use of PCR technology. Although PCR itself 
is a method, the patent in issue actually claimed a product, the enzyme, 
taq polymerase, which was required to perform the PCR method. The 
other two responses to payment of licence fees and/or royalties related 
to an unnamed test kit and an unsure response. One of the respondents 
referring to PCR also mentioned other reagents. 
Table 6: Payment of licence fees or royalties 
Payment of licence fees or 
royalties? Number of respondents (per cent) 
Yes 
Total:                    11 (36) 
PCR/taq:                9 (29) 
Other reagents:   1 (3) 
Test kit:                 1 (3) 
Unsure:                 1 (3) 
No 18 (58) 
Don’t know/no answer 2 (6) 
 
Respondents were also asked whether they had ever received 
notification from a patent holder that the testing they were performing 
was the subject of a patent. They were asked to identify the patent 
involved and state their response to the notification. Only eight (26 per 
cent) respondents stated that they had received notifications and all of 
these related to PCR (see Table 7). One of these respondents also 
commented that they had received a verbal notification concerning the 
haemochromatosis (HFE) test, but this had not been pursued formally. 
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Table 7: Notifications 
 Number of respondents (per cent) 
Yes Total: 8 (26) 
PCR/taq: 8 (26) 
HFE: 1 (3) 
No 23 (74) 
 
On the basis of these results, we concluded that there was little 
indication that holders of patents related to disease genes were actively 
enforcing their patents against Australian genetic testing labs at the time 
that this survey was conducted. Despite this low patent-enforcement 
activity, 45 per cent of respondents expressed concern that gene patents 
may negatively affect access to genetic testing services and 52 per cent 
expressed concern that they could negatively affect prices.140 However, 
we recognised at the time that the looming threat that GTG might 
enforce its exclusivity in respect of BRCA testing remained. 
 
5.3 EUROPEAN STUDIES 
Some years after we completed our survey of Australian genetic 
diagnostic providers, colleagues in Europe examined the impact of 
nucleotide sequence patents on genetic diagnostic testing from the 
European perspective. Naomi Hawkins conducted semi-structured 
interviews with stakeholders involved in public sector genomic 
diagnostic testing in England and Wales.141 She sought to elucidate the 
impact of nucleotide sequence patents from their perspective. She found 
that ‘despite the potential for gene patents to have significant negative 
consequences for genetic testing, in fact, human gene patents have little 
or no impact on practice for those developing genetic tests in the public 
sector in the United Kingdom.’142 Similarly, in a survey of European 
clinical genetics labs, Sibylle Gaisser and colleagues found ‘only a handful 
                                                           
140  See further Nicol and Nielsen, above n 115, Results Chapter 6. 
141  Naomi Hawkins, ‘The Impact of Human Gene Patents on Genetic Testing in the 
United Kingdom’ (2011) 13 Genetics in Medicine 320. 
142  Ibid 320. 
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of cases in which there was patent enforcement’, with only ‘4% (3/77) of 
responding public-sector labs [ever having] been prevented from 
offering a testing service because of a patent-related issue’.143 Despite 
these assurances, however, in each case the authors cautioned that the 
situation could change if patent holders decided to enforce their claimed 
rights. 
 
5.4 THE US STUDIES COMMISSIONED BY THE SECRETARY’S 
ADVISORY COMMITTEE ON GENETICS, HEALTH AND SOCIETY 
In 2010, the journal Genetics in Medicine published a series of studies of 
the impact of patents on particular genetic diagnostic tests in the US.144 
These studies were undertaken by researchers at the Centre for Public 
Genomics at Duke University, who analysed how patenting and licensing 
affect clinical access to genetic testing in the US. The research was 
requested by the Secretary’s Advisory Committee on Genetics, Health, 
and Society (‘SACGHS’) as part of its broader study on nucleotide 
sequence patents and licensing practices and their impact on patient 
access to genetic diagnostic tests. These studies illustrated that 
nucleotide sequence patents could have a range of effects on access to 
healthcare depending on the strategies taken by each patent holder. Of 
the eight tests studied, five showed evidence of the patent increasing the 
price of the tests.  
Colianni and colleagues considered the impact of nucleotide sequence 
patents on access to tests for Tay-Sachs and Canavan disease.145 They 
found that the Tay-Sachs nucleotide sequence patent covering the HEXA 
gene did not stifle research as it was never enforced. The Canavan patent 
over the ASPA gene, in contrast, was restrictively licensed and enforced 
by Miami Children’s Hospital (‘MCH’). Clinical research labs and 
commercial labs received cease-and-desist letters from MCH in 1998, 
which could have stopped them from sequencing the ASPA gene, stifling 
basic research and some clinical research. In 2003, a lawsuit launched by 
groups that had contributed data to the initial research leading to the 
patents was settled, and after this MCH licensed more freely and allowed 
                                                           
143  Sibylle Gaisser et al, ‘The Phantom Menace of Gene Patents’ (2009) 458 Nature 207. 
144  Robert Cook-Deegan and Christopher Heaney, ‘Introduction - Gene Patents and 
Licensing: Case Studies Prepared for the Secretary’s Advisory Committee on 
Genetics, Health, and Society’ (2010) 12 Genetics in Medicine S1.  
145  Alessandra Colaianni, Subhashini Chandrasekharan and Robert Cook-Deegan, 
‘Impact of Gene Patents and Licensing Practices on Access to Genetic Testing and 
Carrier Screening for Tay-Sachs and Canavan Disease’ (2010) 12 Genetics in 
Medicine S5. 
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an exemption for pure research. MCH charged labs a $12.50 royalty fee 
per test to each licensee. When comparing the two tests the researchers 
found that the average price for a test for Canavan disease was higher 
($199.58) than for an unlicensed Tay Sachs test ($111.50) and this 
significant difference could reflect the differing patent enforcement 
strategies.146 
Cook-Deegan and colleagues considered the impact of nucleotide 
sequence patents and licensing practices on access to genetic testing for 
inherited susceptibility to cancer, focusing on breast and ovarian cancers 
and colon cancers.147 In the US, Myriad Genetics used its patent rights 
over the BRCA genes to ensure that it was the only provider of the BRCA 
tests. Genetic testing for familial colorectal cancer, however, is available 
from multiple labs. Colorectal cancer-associated genes are also patented, 
but they have been nonexclusively licensed. The study found that the 
main effect of patent enforcement appears to relate to volume rather 
than price and that any price effect attributable to patents is buried in 
noise and confounding variables. The researchers found that price was 
hard to compare between the two tests.  
Skeehan and colleagues studied the effect of nucleotide sequence 
patents on Alzheimers tests.148 According to the researchers, patents 
have not impeded research in the field. Athena Diagnostics holds 
exclusive licenses from Duke University for three ‘method’ patents 
covering APOE genetic testing (which is linked to late onset Alzheimer 
Disease). Athena offers tests for APOE and genes associated with early 
onset, autosomal dominant, Alzheimer Disease for $475.149 
Powell, Chandrasekharan and Cook-Deegan also examined tests for 
Spinocerebellar ataxia (‘SCA’).150  In the US, Athena Diagnostics holds 
either a patent or an exclusive license to a patent in the case of six 
spinocerebellar ataxia variants and two other hereditary ataxias. Athena 
has enforced its exclusive rights to spinocerebellar ataxia-related patents 
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by sending notification letters to multiple labs. This study sampled views 
of patients and health professionals on access to SCA tests. Roughly half 
of patient respondents to the study had decided not to get genetic tests 
due to price, coverage and reimbursement by insurers and health plans, 
and fear of genetic discrimination. The Athena price for the five most 
common SCAs is $2,300 when ordered individually. A university genetics 
lab can reportedly perform the same five SCA tests for $1,500.151 
Angrist and colleagues considered the impact of gene patents for Long 
QT syndrome.152 Exclusively licensed in 2002, DNA Sciences Inc sent 
cease-and-desist patent enforcement letters to university and reference 
labs offering Long QT syndrome genetic testing. After this there was no 
test on the market for a 1- to 2-year period. From 2005–2008, most Long 
QT syndrome-related patents were controlled by Clinical Data, Inc and its 
subsidiary PGx-Health. Bio-Reference Laboratories secured 
countervailing exclusive patent rights starting in 2006, also from the 
University of Utah, and broke the PGx-Health monopoly in early 2009. 
This created a duopoly for genetic testing in the United States and 
expanded the number of genes for which commercial testing is available 
from 5 to 12. This provides evidence that, in this case, the patents clearly 
increased the cost of tests. 
Chandrasekharan and colleagues considered gene tests for mutations in 
the HFE gene, which is the single most common cause for hereditary 
hemochromatosis.153 Patents owned by Bio-Rad covered the HFE gene, 
related proteins, screening methods and testing kits. In 2007 Bio-Rad 
Limited acquired the key intellectual property and sublicensed it widely. 
In part because of broad, nonexclusive licensing, there are now multiple 
providers and testing technologies, and research continues. The licensing 
involves an upfront payment and a per-test fee of $20.  
Chandrasekharan and Fiffer studied gene tests for hearing loss.154  They 
found that the price of genetic tests for hearing loss did not correlate 
with patent status alone. The price differential between different gene 
tests could not be attributed to patents or licensing because most testing 
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probably did not have sublicenses. They found that one of the tests 
(MTRNR1) was offered by Athena Diagnostics for $365, higher than the 
price of the test offered by universities and hospitals ($150–$285, 
average price $210). Athena’s higher price is not necessarily because of 
patents, however, and other factors may contribute to price difference. 
Testing for the MTTS1 gene, which is not patented, is offered at prices 
comparable (average price $238) to MTRNR1 by universities and 
hospital-based providers. That test is not offered by any commercial 
testing providers, including Athena Diagnostics. They found there was no 
consistent evidence of a premium in testing prices attributable to patent 
status.  
Chandrasekharan and colleagues analysed tests for cystic fibrosis 
associated with mutations of the CFTR gene.155 The University of 
Michigan and the Hospital for Sick Children (‘HSC’) chose to license their 
patent nonexclusively. The research shows how patenting and licensing 
decisions by the University of Michigan, and the HSC allow for significant 
research without unduly hindering patient access or commercial 
markets. The initial license fee for kit licenses is $25,000, which has not 
changed in over 15 years. An in-house commercial test is $15,000 (plus 
licensees have to pay 3.6 per cent royalty).156 
Based on these studies, the SACGHS concluded that there was a ‘near 
perfect storm’ developing ‘at the confluence of clinical practice and 
patent law’ and there was evidence that patents had already limited the 
potential of some genetic tests.157 The SACGHS found that knowledge of 
the genetic foundations of disease had increased exponentially and, at 
the same time, the cost of using genetic testing technologies had 
decreased. Genetic testing is progressively being used to personalise the 
delivery of medicines and medical treatments.158 At the same time, the 
SACGHS concluded that patenting and enforcement strategies in the US 
threatened to undermine the potential of genetic technology, and that 
few mechanisms exist under US patent law to mitigate these impacts (for 
example a compulsory licensing regime or broad research exemption).159 
They posited that while patent incentives are arguably not essential for 
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the development of genetic diagnostic tests, the existence of patents 
over aspects of genetic technologies threatens to hinder their delivery.160 
The SACGHS also heard presentations from experts during the course of 
its study and gathered further information and perspectives on its draft 
report through the solicitation of public comments.161 The Committee 
concluded that there was evidence of denial of access to tests not 
covered by insurance, difficulties in obtaining second opinions and one 
instance where a patent dispute restricted access to tests for an 18-
month period.162 Although the Committee found that patents or 
exclusive licences could stimulate development of a genetic test, they 
found no instances where possession of exclusive rights was a necessary 
prerequisite.163 Ultimately, the Committee recommended the creation of 
exemptions from patent infringement for use of genetic tests for patient 
care purposes and for use of patent-protected nucleotide sequences for 
research purposes.164  
Although the US government decided not to include the exemptions 
recommended by the SACGHS in the Leahy-Smith America Invents Act 
2011, s 27 of the Act expressly required the Director of the US Patent and 
Trademarks Office to conduct a study into second opinion testing, with a 
requirement that this study be completed nine months from the Act’s 
date of enactment. Anecdotally we understand that the study has been 
completed but the report of the study has not been released by the US 
government. 
 
5.5 MORE RECENT AUSTRALIAN RESEARCH AND OTHER REPORTS 
OF PATENT ENFORCEMENT ACTIONS 
One of us (Nicol) and John Liddicoat undertook another survey of genetic 
testing providers in 2013.165 Before the survey was drafted, interviews 
were conducted with managers from four leading Australian providers of 
genetic diagnostic testing services to assist with survey design. Email 
invitations to participate were sent to 37 of the lab managers listed on 
the NATA website for whom email contact details could be verified. Of 
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the 37 invitees, 28 accessed the survey and 24 completed it (a response 
rate of 65 per cent).  
The results of this survey showed that the number of respondents 
actually paying licence fees and/or royalties has decreased from the 
2002–2003 survey, largely because the PCR patents had long expired. In 
the Nicol-Liddicoat study, of the three respondents who reported paying 
fees, only one identified the relevant test: ACTN3. This genetic test is not 
linked to a disease, but related to athletic performance.166 The applicant 
at the time was listed as GTG,167 although the applicant now listed on the 
granted patent is Specialist Diagnostic Services Pty Ltd. The patent, which 
only claims the genetic diagnostic method, not the nucleotide sequence, 
was applied for on 15 September 2003 and sealed on 21 August 2008. 
Litigation regarding the equivalent US patent was ongoing in the US at 
the time we undertook our survey,168 but as far as we are aware this was 
the first time its enforcement has been recorded in Australia. 
Notably, more notifications of patent rights from third parties were 
reported when compared with the earlier study. Questions concerning 
these notifications were divided into ‘before 2010’ and ‘since the start of 
2010’, to give us a picture of the changing landscape over time. Nine 
respondents (37.5 per cent) indicated they had received notifications 
before 2010, and three respondents (12.5 per cent) indicated they had 
received notifications since the start of 2010. A number of respondents 
who identified which test the notification related to said that it was for 
BRCA. Of the nine respondents that received notifications before 2010, 
four said they related to BRCA testing, one identified PCR, one could not 
recall details of the notification, and one stated ‘maternal cell 
contamination testing for prenatal samples using STR methodology’ 
(‘maternal-prenatal testing’, also known as non-invasive prenatal testing 
or NIPT – we return to the patent issues associated with this test later in 
this occasional paper). 169 Of the three respondents who said they 
received notifications post-2010, one stated ‘BRCA’, one could not recall 
and the other again said maternal-prenatal testing.  
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Interestingly, the majority of respondents indicated that they were 
unconcerned or only marginally concerned about the risk that third-party 
patent rights could affect the provision of genetic tests now or in the 
future. This marks a significant shift in opinion from 2003. One 
respondent identified the SCN1A patent as being of concern. The SCN1A 
gene is related to Dravet syndrome, a severe form of childhood 
epilepsy.170 This disease requires early diagnosis because seizures can 
cause brain damage and children can lose the ability to function 
independently. About 70 to 80 per cent of children suffering from Dravet 
syndrome can be diagnosed early using a test for the SCN1A gene. The 
applicants on the Australian patent for SCN1A are Bionomics Ltd and 
McGill University,171 and the patent had been exclusively licensed to 
GTG.172 There had previously been recorded instances of GTG charging 
higher prices for the test for SCN1A, than providers in other 
jurisdictions.173 However, no respondents to this survey indicated a 
licence fee had actually been paid for the test, nor that a notification had 
been received regarding potential infringement. 
There is some further commentary on nucleotide sequence patents174 
affecting the cost of healthcare, published through newspaper articles 
and in the Senate Reports. In the Senate Community Affairs Reference 
Committee Gene Patent Report, for example, mention is made of a 
submission from the RCPA that included reference to the enforcement 
of the IgH and TCR gene rearrangement tests performed on cancer tissue 
from patients with lymphoproliferative disorders or acute myeloid 
leukaemia.175 The Report states that US based patent holder, 
InVivoScribe Technologies, approached all Australian labs performing the 
tests and insisted they switch to the exclusive use of the company’s kit 
and method or obtain a sub-licence to use their own tests. The RCPA 
noted that the cost of the in-house test for labs was $28 per patient 
(excluding labour and other costs) while the cost of the provider kit was 
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$292 per patient (excluding labour).176 The RCPA had purportedly 
received evidence of switching to use the provider test kit, or ceasing 
testing altogether.177 We had not been informed of this enforcement 
action in our previous empirical studies. We understand that IP Australia 
has undertaken some analysis of these patents.  
The SCN1A test for Dravet syndrome, referred to above, was raised in the 
popular press around the time of the Senate Community Affairs inquiry. 
It was noted that testing for Dravet syndrome had become ‘devastatingly 
rare due to patent-protection issues’.178 According to the report, GTG 
threatened to sue Australian public hospitals if they continued testing 
babies for SCN1A. Dr Deepak Gill, head of neurology at the Children’s 
Hospital at Westmead said that if they could conduct the test on-site, the 
clinic would test 50 per cent more infants for the gene.179 John 
Christodoulou, director of the Westmead Hospital’s Western Sydney 
Genetics program, stated that his lab could not risk performing another 
version of the SCN1A test because GTG may bar him from testing or may 
impose a prohibitive royalty. It appears that, as a result, hospitals had to 
send blood samples to Scotland for testing, at a cost of $1,800. Although 
this is similar to the fee charged by GTG, Dr Gill advised they chose it in 
preference to the GTG test because he had more confidence in it. 
Australia stopped screening all but those children whose medical profiles 
were most dramatically suggestive of the condition. However, in a 
written statement to the Senate Committee Inquiry into Gene Patents, 
Dr Gill stated that he was ‘not aware of any evidence that the licensing 
of one lab to carry out the tests has had a significant negative impact on 
research in the field of SCN1A testing’.180 
Another news report at around the same time noted that the Victorian 
Clinical Genetic Testing Service wrote to the scientists who had identified 
gene mutations for Long QT syndrome, hoping to gain some collegial 
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insight when they struck some difficulties in their research.181 Instead, 
they received a letter from lawyers informing them that their team was 
infringing patent rights: an American biotechnology company, PGx-
Health, held the Long QT patent. The report states that a licence was 
eventually negotiated for a large, undisclosed sum and the research 
continued.182 
In Canada, following enforcement threats by the US-based company 
Transgenomics relating to its patents over Long QT Syndrome, lawyers 
for the Children’s Hospital of Eastern Ontario (‘CHEO’) challenged the 
validity of the Canadian patent. In a settlement agreement in March 
2016, Transgenomic  agreed to provide CHEO and all other Canadian 
public sector labs and hospitals the right to test Canadians for the 
condition on a not-for-profit basis.183 Dr Gail Graham, chief and clinical 
geneticist at CHEO, stated that being able to test for the disorder in 
Canada will cost half of what it did to send material to a US lab.184 A 
recent empirical study concluded that agreements such as those entered 
into by CHEO, have the potential to positively alter the landscape for 
genetic testing in Canada by providing a blueprint for achieving access to 
any patented test on favourable terms.185 
 
5.6 THE NUCLEOTIDE SEQUENCE PATENT LANDSCAPE  
One of the ongoing challenges in this area has been understanding the 
extent to which the landscape for genetic diagnostic testing is actually 
occupied by nucleotide sequence and method patents. The Cho and Merz 
studies in the early 2000s identifying problematic patents relating to the 
provision of genetic diagnostic tests in the US, and our mapping of 
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Australian equivalents described earlier in this occasional paper, provides 
some assistance in this regard.  
In later work in 2005, Kyle Jensen and Fiona Murray used bioinformatics 
techniques to compare gene sequences that were included in US patents 
with publicly available human genome sequence information, concluding 
that ‘nearly 20% of human genes are explicitly claimed as US IP’.186 
However, Chris Holman subsequently argued that this overestimated the 
percentage of human genes subject to patent claims, because not all of 
the sequences identified in the patents were explicitly claimed.187 Patent 
landscaping in other jurisdictions suggests fewer DNA and method 
patents exist outside the US.188 Analysis of patterns in filing activity 
indicate a surge in filing in the 1990s which did not continue into the 20th 
century. It also revealed that many of the patents filed during the 1990s 
were not pursued to examination, and others that were granted were 
allowed to lapse.189  
To provide a more accurate picture of the impact of individual patent 
claims on genetic diagnostic testing, a group in Belgium led by Geertrui 
Van Overwalle undertook a manual claim-by-claim analysis of patents 
claiming rights linked to the 22 most commonly undertaken genetic 
diagnostic tests (‘the Belgian study’).190 They found that 15 of those tests 
could potentially be blocked by patents in the US or Europe, in the sense 
that they would be almost impossible to circumvent if best practice 
guidelines were followed in performing the required test. A total of 35 
patents were identified as having claims that were potentially blocking, 
24 in the US and 11 in Europe. Method claims were generally found to be 
more problematic than sequence claims in terms of being almost 
impossible to circumvent.  
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Liddicoat, Nicol and Whitton conducted a follow up study in other 
jurisdictions, using European Patent Office (‘EPO’) lists of ‘simple’ and 
‘extended’ families of the patents identified as blocking in the Belgian 
study.191 To be clear, we did not engage in claims analysis, but focused 
more on the status of the patent families. The results of this study 
provided evidence that the likelihood the specific set of patents 
identified by Huys et al could impede genetic testing on a global scale is 
remote, because many of them were not in force in countries other than 
the US at the time the study was undertaken. In Australia, for example, 
four of the relevant extended family patents and two of the simple family 
patents were in force when the study was undertaken. On this basis, we 
argued that it would be unwise to extrapolate concerns about the 
overreach of gene patents from the US, to other jurisdictions. Further, 
the small set of patents remaining in force at the time the study was 
undertaken have now expired. This is not to say that there are no 
relevant patents in the genetic diagnostic testing landscape, only that the 
patents that have been identified as being most likely to have a 
pernicious effect are no longer features of that landscape.  
 
5.7 ECONOMIC ANALYSIS OF NUCLEOTIDE SEQUENCE PATENTS  
Very few economic studies have been undertaken examining the 
economic consequences of granting nucleotide sequence patents. 
Notably, in May 2013 the Centre for International Economics (‘CIE’) 
prepared an extensive Report for IP Australia which reviewed the 
economic impacts of isolated human nucleotide sequence patents.192 
The authors completed a literature review, interviews with stakeholders, 
analysis of the AusPat patent database, and collected what information 
they could on the economic activity of relevant organisations.193  
Quantitative analysis was used to estimate the direct impacts of isolated 
human nucleotide sequence patents.   
Among other things, the Report provided an estimate of the number of 
patents ever granted in Australia based on nucleotide sequences.194 The 
estimate was that 61 per cent of patents were for partial sequences, 24 
per cent were for full-length sequences and 15 per cent were method 
only. Of the partial sequence patents, 68 per cent had a counterpart in 
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nature. Of the full-length sequence patents, 80 per cent had a 
counterpart in nature. The authors also found that only a small number 
of patents based on nucleotide sequences were still in force at the time 
of writing the Report: 30 per cent of all full-length sequences and 37 per 
cent of all partial sequences.195 The authors found that the number of 
partial sequence patents fell dramatically after the Human Genome 
Project was completed.196 The Report states that this international 
scientific project led to increasing difficulty establishing novelty for 
nucleotide sequence patents. After the completion of this project, 
method patents made up much more of the patent cohort.197  
The Report also considered the impact on price of genetic diagnostic 
tests of patents, but was unable to draw any firm conclusions.198 The 
authors suggested that there was some evidence of a price premium on 
some genetic diagnostic tests resulting from patents, but noted that 
patents are just one factor attributable to the cost of a genetic test. Other 
factors include the ‘size’ of the gene, and whether it forms part of a 
panel.199 
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CHAPTER 6 
WHAT WE LEARNED ABOUT THE IMPACT OF IP ON 
GENETIC DIAGNOSTIC TESTING FROM THE 
INTERVIEWS  
 
6.1 IMPACT OF IP ON AVAILABILITY OF TESTING 
The previous section of this occasional paper provides an account of 
earlier survey data, media reports and other anecdotal evidence showing 
that test providers received cease and desist letters on several occasions 
during the early 2000s. These reports aligned with enforcement action 
being taken in overseas jurisdictions, particularly the US. In this study, we 
asked our interviewees to confirm whether or not they had been subject 
to enforcement action by patent holders at any time. Much of what they 
reported aligns with what we gleaned from our earlier surveys and 
interviews in 2002–2003, and in 2013. 
A number of interviewees reported receiving cease and desist letters 
from patent holders or licensees in relation to certain tests. Several 
interviewees affirmed that their labs had received cease and desist 
letters in respect of BRCA testing. In the case of publicly funded labs, this 
enforcement action slowed testing only briefly – testing soon resumed 
once it became clear that legal proceedings were unlikely to be 
undertaken and the decision was made by relevant state-based health 
departments to continue to offer the tests. One interviewee from a 
standalone pathology lab reported a three to six-month delay in testing 
due to uncertainty over whether enforcement would ensue. As another 
interviewee explained: 
It didn’t really affect us, we never stopped testing because of 
the threat of litigation. I remember when the BRCA thing came 
out, there was a lot of correspondence between public 
pathology and the Minister for Health to get advice as to how 
to proceed. From what I remember at the time it was … you 
know, proceed as currently until … notified, until a change. … I 
think there was (sic) some decisions made at a federal 
government level that then rolled down, and we all went … we’ll 
keep doing what we are doing anyway. 
An interviewee from a state based health department corroborated this: 
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So at the time that … Myriad and GTG were sending out letters 
to everyone … I have a recollection that if we had to pay the 
additional cost to GTG to do the test, it would be an additional 
half a million dollars (per year) at the time to the (state) 
government. 
At the time state government representatives reportedly met and 
discussed the possibility of application for a compulsory licence should it 
become necessary. This interviewee stated that federal government 
support for this approach was given. Although this course of action was 
not ultimately necessary because GTG abandoned enforcement action, it 
highlights the collective power of publicly-funded test providers in 
averting enforcement action. 
In the case of private labs, during the period that the BRCA patent was 
valid, it would appear that no private lab in Australia (aside from GTG) 
tested for BRCA mutations. One interviewee from a private lab 
commented that there were no private providers offering the test at the 
time and this was probably due to a fear of patent enforcement: ‘I 
literally think that everyone in the private space just thought this is too 
much hassle, we’re not going to do it.’ Hence, cease and desist letters 
(which were largely ignored), were received only by public labs. Another 
interviewee (from a public lab) indicated that the BRCA patents have 
almost certainly prevented private labs offering BRCA testing, despite 
public labs working through the enforcement threat by GTG.  
It remains the case that Genomic Diagnostics (having acquired the 
business from GTG) is the only private provider in Australia offering BRCA 
testing. It is not clear why more private providers have not entered this 
market. One possible reason is that private providers are concerned that 
Myriad’s diagnostic method patent claims (which remain on foot in 
Australia), could be enforced against them. Another reason is that the 
extended period during which GTG was able to exercise a monopoly in 
BRCA testing helped establish it in an unassailable market position as the 
sole private provider. In any case, from the public perspective, any 
deleterious effects that might result from this are ameliorated, as the 
provision of testing by the public component of the industry has ensured 
that a relatively competitive environment has been maintained. The fact 
that the industry is structured in this manner in Australia has a strongly 
protective effect in that it insulates the industry from any provider being 
able to charge excessive prices for tests.  One interviewee representative 
of a state health department who has extensive experience in the genetic 
diagnostic testing industry observed rather acutely that during his time 
at a standalone public lab: 
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[A]bsolutely, the lab had cease and desist letters. That 
happened to all, I think, major labs. The laboratory we were 
running was a fairly major provider in the public sector and 
there was a lot of confusion around this. GTG weren’t pursuing 
this and then all of a sudden they were … there were 
negotiations around that, more informal I think, than formal, 
but at the end of the day it sort of kept going along. …[W]hat 
sort of happened there, their main referral source was through 
the public system at that point in time. So it was sort of a little 
bit how much do you upset this. They were playing a fine 
balancing game, as well … as trying to maintain company and 
shareholder interests and things, but also not impact too much 
on what might be referred through. 
In our view this point about patent holders relying on public labs as a 
source of referrals is a critical one, in that it provides one compelling 
explanation for why enforcement threats are followed through only 
infrequently. It would appear that GTG made a concerted decision not to 
proceed with enforcement action and to allow public labs to continue 
testing. This was probably due primarily to the public backlash that would 
ensue should enforcement proceedings be taken, but also to the fact that 
a cessation of referrals from public labs would be detrimental to GTG’s 
business. 
There have been few other instances of enforcement. Some interviewees 
reported paying licence fees to Roche in respect of the use of PCR 
technology, as reported in our 2002–2003 survey, and several also 
mentioned enforcement action in respect of haemochromatosis testing 
(although it hadn’t specifically impacted on them). Two interviewees 
recalled receiving cease and desist letters more recently in respect of the 
SCN1A patent, which we had also received evidence about in our 2013 
survey. Further, one of these interviewees (from a pathology lab based 
at a public hospital) reported that that they had stopped testing for 
SCN1A for a period of approximately five years upon receiving a cease 
and desist letter. Aside from this isolated example, very little of this 
enforcement action would appear to have resulted in the cessation of 
testing in this space, particularly in public labs. As one interviewee from 
a public lab put it (in relation to SCN1A patent enforcement): ‘Yes, I 
vaguely remember that one, again, impact level out of 1 to 10, 1.’ These 
results align with earlier media reports of a cessation in testing, 
demonstrating that although there may have been instances where 
testing was affected, this impact was not universal. 
Another interviewee from a standalone pathology lab described 
enforcement action during 2011 when they began testing for Long QT 
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Syndrome. As we noted above, this issue was reported in the media at 
the time. The test involved an in-house test rather than a test kit. The 
patent holder (Transgenomic) demanded an up-front fee and a royalty 
payment for each patient tested (and subsequently billed). Testing 
continued after a period of discussion but no follow-up demand for 
payment was ever received. A strategy of ‘wait and see’ would appear to 
have reaped rewards for the lab in question: ‘[T]esting still continued on, 
labs still continued on doing their testing and waiting and waiting for the 
letter to arrive and they didn’t ever pursue it.’ 
Two interviewees mentioned the patented test for FLT3 internal tandem 
duplication testing for patients with acute myeloid leukemia, held by 
InVivoScribe.200 Their view was that this patent had limited impact 
because the only restriction on clinicians related to use of the 
InVivoScribe test – alternative methods of testing were available and the 
strict enforcement practices seen in the Canadian system were not 
replicated in Australia. According to these interviewees, they used 
alternative tests that, in their view, were better tests anyway.  
A similar situation has arisen more recently with regard to NIPT testing, 
in that Illumina (which holds patents over the Harmony pre-natal test) 
and Sequenom (with whom Illumina has pooled its patents), have 
brought legal proceedings against two Australian companies that use 
Roche’s NIPT test (Sonic and Australian Clinical Laboratories). The 
breadth of Illumina’s process patents were commented on by two 
interviewees, in that they give broad rights over sequencing cell-free 
fetal DNA, present in maternal blood. While these patents haven’t 
completely eliminated competition in the NIPT market because there is 
still scope to employ alternative methods of testing, the outcome of the 
litigation will be a critical element in the development and use of 
alternative tests. We come back to the NIPT litigation again later in this 
occasional paper. 
As for future developments, there is still a risk that patents generally may 
have an impact on the delivery of diagnostic genetic tests in the next 
generation sequencing sphere. As one interviewee noted: 
I wonder as we are moving forward … how really complex it 
becomes if we are doing genomes and exomes and there are 
patents on just about everything. … [I]n a typical genome, we’re 
                                                           
200 For discussion of corresponding European patents see German Supreme Court 
Upholds and Strengthens Invivoscribe FLT3 Patent Position (29 March 2016) Market 
Wired <http://www.marketwired.com/press-release/german-supreme-court-
upholds-and-strengthens-invivoscribe-flt3-patent-position-2109605.htm>. 
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finding a million variants. For one patient. So some of those are 
going to turn out to be something you want to follow up. Then 
you’re not going to sit there and search for patents on all of 
those. Even if you did find one, who are you going to pay and 
what are you going to do about it? 
The reality is that, to clinicians, patents do not become a problem until 
they are enforced and, even then, there have been very few instances in 
Australia where enforcement has proceeded to the point where it has 
impacted on delivery of tests. As this particular interviewee commented, 
Australia is a small market in the scheme of genetic diagnostic testing 
markets. It would be reasonable to conclude that genetic diagnostic 
testing remains one instance where patent enforcement threats have 
never had a significant impact:  
public pressure generally trumps moves to litigate, and the fact 
that a substantial component of the testing industry in 
Australia is publicly funded, means that there is a strong 
incentive for patent holders to permit some degree of market 
competition.  
 
6.2 IMPACT OF IP ON COST OF TESTING 
A general consensus across interviewees was that the D’Arcy decision will 
have minimal impact on the cost of genetic diagnostic testing in Australia. 
If D’Arcy is to have any impact at all, this effect is unlikely to be discernible 
and would be extremely difficult (if not impossible) to separate out. Data 
indicates that the price of genetic diagnostic testing is fluid, in light of the 
dramatic technological changes that have occurred over the past few 
years. One reason why we posit that the impact of D’Arcy will be minimal 
is because the impact of nucleotide sequence patents themselves on the 
cost of testing has been minimal. Certainly, interviewees acknowledged 
that patents do impact on the price of testing if commercial kits are used 
and those kits incorporate a royalty component. As one provider from a 
research institute stated in response to a question about whether test 
kits that were subject to a patent are inevitably higher: ‘Oh they certainly 
are. If you use kit based tests which, you know, have those sort of patents 
(sic) included in them, they are very much higher than the laboratory 
developed tests.’ As to whether the D’Arcy decision may have prompted 
a decline in the cost of commercial test kits, this interviewee responded 
that instead, ‘prices have gone up because of the weak Australian dollar’. 
On the whole, however, there was a view that royalty payments feed into 
costing of tests on only a very limited basis, given the range of other 
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factors that potentially impact on cost. Changing technology was the 
biggest factor identified by interviewees as having brought prices down:  
Oh hugely. It’s actually put a lot of pressure on us because of 
the different type of laboratory and skill set that our scientists 
need. … [W]e do much more for much less but because we are 
doing so much more we are under quite a lot of pressure. 
Table 8 provides a comparison of test costs in 2003 and 2017. The 2003 
data were obtained in surveys conducted as part of the Nicol and Nielsen 
study. The 2017 data comprise a combination of publicly available 
information on costs from pathology providers in Australia, and data 
obtained during interviews. The data on whole genome sequencing 
combine publicly available information (2006 and 2017 data) and 
information gleaned during interviews (2017 data).  
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Table 8: Price comparison between 2003 data and 2017 data 
Test type Price (public lab): 2003 
Price (public lab): 
2017 
Price (private 
lab): 2017 
Haemochromatosis $31.50 (no charge to public patients) $31.00 
$60.00 (MBS rebate 
of $31.00, item no. 
73315) 
Fragile X $80–$200 $86.15 
$101.30 (MBS 
rebate of $86.15, 
item no. 73300) 
Cystic Fibrosis 
$80 (single gene) - 
$200 (multiple 
mutations) 
$150 $310 
BRCA1 and BRCA2 
$1,800–$2,500 (no 
charge to public 
patients) 
$425–$1,000 
$500–$700 for BRCA 
+ extra genes 
(note MBS item no. 
73295 germline 
BRCA testing 
$1,119.80) 
Inherited cancer 
predisposition panel 
(esp. breast, ovarian, 
prostate, pancreas) 
Based on cost per 
gene $600 (14 genes) 
Overseas company 
Color Genomics 
charging US$275 (30 
genes) for tests 
ordered online 
through a medical 
practitioner 
Single gene test $200–$1,000 
$50–$400 
(depending on 
complexity of gene 
being tested) 
$40–$410 
Whole exome Not available Approx. $1,000 $1,000–$3,000 
Whole genome In 2006: $14 million 
$1,500–$4,500 
(depending on level 
of interpretation of 
results) 
$600–$4,500 
(depending on level 
of interpretation of 
results) 
 
The table reveals a dramatic decline in test costs in a vast majority of 
instances, this being due largely to technological developments. The 
most marked cost reduction clearly relates to whole genome sequencing. 
BRCA testing is also markedly cheaper now, and interviewees reported 
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that the cost will continue to decrease. The cost of sequencing other 
single genes has also decreased, although it is difficult to provide one 
single comparative figure in this context because there is huge variance 
in the complexity of different genes. In some cases, it would appear that 
test prices have actually increased recently. For example, the testing 
prices of public and private labs for cystic fibrosis, as shown in Table 8, is 
higher in 2017 than in 2003. This is fundamentally due to the fact that 
testing methods have changed and knowledge of affected genes is far 
greater. In other cases, test prices appear to have changed only 
marginally. As one interviewee from a pathology lab in a public hospital 
put it: 
Certainly, … they are still expensive tests. We would have 
charged $1,500 for a fibrillin test in the past. You’d probably 
still pay $1,500 but you’d get 20 times as much information. … 
[T]here will probably be real costs coming down as well. At the 
moment they are probably similar costs but you’re just getting 
a lot more. 
The costs charged by labs for haemochromatosis and Fragile X tests have 
also remained fairly steady and they generally reflect the scheduled 
rebate amount. As pointed out earlier, although these rebate amounts 
were perceived by interviewees to be very low, they probably reflect the 
cost of performing the test. 
The impact of competition within the market should also not be 
underestimated. Private providers now face competition from overseas 
competitors in many aspects of genetic testing. This certainly applies to 
BRCA testing: as Table 8 reveals, companies like Color Genomics are now 
offering BRCA panel testing for $275, and marketing aggressively to 
patients and GPs. This marketing approach (while testing overseas) 
effectively sidesteps the requirement to be NATA accredited, and as an 
interviewee from a state health department stated: 
That sort of thing … has probably had more of an impact on the 
prices than ever, because, and indirectly, that’s probably 
because now they are allowed to operate and offer those tests 
whereas in the US Myriad had had them shut down. It’s not so 
much the High Court decision in Australia that’s affected it, it’s 
the Supreme Court decision … in the US that’s allowed the 
market in the US to open up … and then those companies have 
(raised) people’s awareness of the costs in Australia. That’s 
probably had more of an effect, I think, than the … High Court 
decision in Australia. 
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Further to this, the impact of patents is more likely to be felt in respect 
of method rather than nucleotide sequence patents, and this has been 
the case for some considerable time. Lack of choice over sequencing 
equipment and methods of use are taken as a given by test providers. 
Coupled with servicing obligations, there is limited choice for test 
providers as to use of the equipment and associated sequencing assays 
of industry monoliths such as Illumina. Illumina manufactures state-of-
the-art sequencers, which are used by most test providers in Australia. 
Illumina has a number of patents over its sequencing hardware, and 
offers maintenance services in conjunction with its machines. There is 
strong take-up of servicing by Illumina: they are market leaders in 
sequencing machines and generally their associated service offerings are 
taken up. A requirement of NATA accreditation is adherence to a strict 
maintenance schedule. 
Most of the comments made about sequencing companies such as 
Illumina were positive – their sequencers are extremely good as are their 
associated services (according to most interviewees using this 
equipment, although one interviewee was very critical). Nonetheless, 
there is little doubt that their near-monopoly position influences the cost 
of genetic testing far more than nucleotide sequence patents would 
appear to have done. Likewise, Illumina’s business model is predicated 
on use of Illumina reagents with their sequencing machines: 
I’m sure that they are charging up a lot more for the reagents 
that we use than it costs them to make them, like a lot, lot 
more. And I would like to offer our tests for less than they cost, 
but … we’re not sort of marking it up by five times whereas I’m 
pretty sure that they are. But that’s them I guess. 
Illumina’s ability to charge high costs for its reagents hinges on test 
providers continuing to use its sequencing equipment and methods. 
Although it is possible to use competing reagents,201 its sequencing 
hardware relies on use of its sequencing cartridges. The price of 
hardware was reported to be tied to use of Illumina’s reagents. However, 
it is clear that Illumina’s technological supremacy is the predominant 
factor in its control of the sequencing market: 
All that it means is that someone has to come up with a new 
way of sequencing and a new chemistry. Whereas, if you say 
any method to look at this thing you cannot use, that is quite 
                                                           
201  Although note that one interviewee from a standalone pathology lab made a 
comment that contradicts this: ‘Once we go with their sequencers we are pretty 
much committed to their reagent. I’m not aware of any other that will work on their 
equipment.’  
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different. But no one yet has come up with a way that is better 
than Illumina’s way of doing it. 
A further interesting fact that can be gleaned from interviews is that 
Illumina’s strategy in developing its sequencers to be compatible with 
rival reagents is deliberate. Presenting labs with this choice assists in 
ensuring maximum uptake of its sequencers. One interviewee estimated 
Illumina’s market share of the sequencing market at 80–90 per cent. 
Another interviewee commented on the potential for Beijing Genomics 
Institute (‘BGI’), a global sequencing centre based in China, to attain a 
significant share of the sequencing market. BGI has made great inroads 
in the development of the next generation of sequencing equipment. 
Like Illumina, BGI has stringently protected its proprietary position. 
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CHAPTER 7 
CONCLUSION 
   
In conclusion, as we hypothesised, the research we have conducted for 
this project provides limited evidence that the D’Arcy decision has had a 
quantifiable impact on the cost of genetic diagnostic testing in Australia.  
Has enforcement by patent holders impacted on the delivery of 
genetic diagnostic testing? 
Our research demonstrates that there have been no long-term 
interruptions to testing despite moves to enforce patents in particular 
instances. An important explanation for the fact that these moves have 
not been followed through is the size of the Australian genetic diagnostic 
testing market. Particularly for patent holders based overseas, pursuing 
publicly funded labs is not as worthwhile as it would be in more populous 
jurisdictions. It is interesting that the only instances of persistent 
enforcement in Australia (such as the BRCA example) involve Australian 
patent holders or licensees. However even these more ‘determined’ 
attempts to compel enforcement have met with limited success, as 
testing in public labs has been allowed to continue. 
Private labs are unlikely to enjoy the same immunity from enforcement, 
as demonstrated by the example of BRCA testing. While we cannot be 
clear that the decision by private providers to refrain from offering BRCA 
testing was due directly to Myriad/GTG’s enforcement action, it would 
appear to be an indirect impact. While this has a bearing on the ability of 
these labs to provide particular testing services, it has limited impact on 
patients who may still access testing from public labs as either public or 
private patients.  
Has D’Arcy had an impact on the price of genetic diagnostic testing? 
The structure of the largely publicly-funded Australian industry has also 
influenced the price of testing. Competition between labs generally and 
public labs in particular, has to some extent siloed these labs from the 
effects of patent enforcement, especially with regard to the BRCA 
patents. Public labs continue testing and charge no more than necessary 
to permit them to recover costs. Clearly if GTG had continued its 
enforcement line and charged unreasonable royalties this conclusion 
Conclusion 
 73 
may not be possible. But it is reasonable to assume that further attempts 
to enforce the BRCA patents would have been met with a similar level of 
resistance from public labs. 
There is no doubt that there are areas where patents do impact on the 
price of genetic diagnostic testing. Patents held by companies 
manufacturing test kits have almost certainly been factored into the cost 
of those kits, but this is not something that our interviewees were overly 
concerned about. It is accepted as a cost of doing business in this space, 
and generally interviewees felt that in the instances where commercial 
kits were purchased (as opposed to kits being developed in-house), they 
were well worth the premium price paid for them. It is also worth noting 
that there are many instances where commercial kits are available but 
tests developed in-house are used in preference. Essentially, test 
providers use commercial kits where they are available, where they are 
effective, and where the price charged for them is reasonable. 
Otherwise, they tend to create their own tests. 
One reason why there is no general objection to commercial kits is that 
they usually involve patented methods. Method patents were viewed by 
interviewees as involving legitimate claims. This is not necessarily the 
case where claims are very broad, as may be the case with the NIPT 
patents held by Illumina and Sequenom. Generally speaking, however, 
patented testing methods are not viewed as being overly far-reaching. It 
is worth reiterating that the High Court in D’Arcy did not consider method 
claims, therefore we would not expect the decision to impact on the 
ability of method patent owners or licensees to enforce these patents.  
Method claims extend beyond the provision of tests kits. Patents held by 
Illumina over sequencing methods, for example, provide it with an 
unassailable market advantage. Nevertheless, its technology and 
associated methods have set the industry standard, and interviewees 
were generally very positive about its IP position.  
In short, it is possible that D’Arcy may have had some impact on the price 
that patent holders can charge in respect of tests that infringe patents 
over patented nucleotide sequences. Our interviews provided very little 
evidence, however, of knowledge of broad patents over cDNA, let alone 
compliance with those patents. If providers are unaware of the existence 
of patents, those patents cannot currently be impacting on price. 
If D’Arcy has had an impact, is this impact quantifiable? 
Even if the D’Arcy holding has factored to some degree into the price 
charged for tests (particularly the BRCA test), it is difficult to see how this 
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effect could be separated out from the other factors impacting on cost. 
In a good many cases, dramatic technological development and 
competitive pressures have undoubtedly had a greater effect on prices 
charged than the relevant patents. It would therefore be extremely 
challenging to attempt to quantify the impact of D’Arcy on prices charged 
subsequent to the High Court’s decision.
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CHAPTER 8 
FUTURE ISSUES 
    
We have seen from our interviews that many in the field of genetic 
diagnostics see the D’Arcy decision as correcting an anomaly in patent 
law. For them, nucleotide sequences as they exist in nature are not and 
never should have been patentable subject matter. Whether the decision 
has any practical impact for them is, however, a different question. It is 
questionable whether nucleotide sequence patents were ever of any real 
value to their holders in Australia, or a threat to users in the context of 
genetic diagnostic testing. By the time the D’Arcy decision was handed 
down, the early broad nucleotide sequence patents issued in the 1990s 
had had their day (if indeed there was ever a day to be had), as illustrated 
by the fact mentioned earlier that the patent in issue in D’Arcy had 
already expired before the decision was released. This is not to say that 
no other existing patents and no future applications might be affected by 
the D’Arcy holding.  
 
8.1 FURTHER ANALYSIS OF NUCLEOTIDE SEQUENCE PATENTS 
AND PATENT PROSECUTION 
It was not within the ambit of this project to analyse the validity of 
nucleotide sequence and method patent claims at the present time, 
post-D’Arcy, nor the prosecution of patent applications including these 
claims post-D’Arcy, although this might be warranted at some stage. A 
number of researchers have been undertaking such analyses of the US 
patent landscape both pre- and post-AMP. For example, even before the 
AMP case was decided, Greg Graff and colleagues estimated that if the 
Supreme Court invalidated claims to isolated naturally occurring 
nucleotide sequences, only a small percentage (just over ten per cent) of 
the total population of nucleotide sequence patents would be 
invalidated.202 The reason they gave for this finding was that the 
tendency to claim isolated sequences was already steadily decreasing 
with far more claims to non-natural constructs. Moreover, only 41 per 
cent of those patents likely to be invalidated claimed human nucleotide 
sequences.  Post-AMP, Aboy and colleagues examined patent filings and 
patent prosecutions for subject matter relating to nucleotide 
                                                           
202  Graff et al, above n 188. 
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sequences.203 They observed that such applications continue to be filed, 
despite the decision of the Supreme Court invalidating Myriad’s patents, 
although there is an expected drop off in claims referring to ‘isolated’, 
‘purified’ or ‘natural’ sequences. As noted by Graff and colleagues pre-
AMP, there is an observable trend towards more claims to non-natural 
constructs, as well as method claims. 
As far as we are aware, no analysis of patent filing and prosecution 
patterns have been undertaken in Australia post-D’Arcy. It may be 
appropriate for such analyses to be undertaken at this time, or in the 
near future. We suggest that it might be particularly worthwhile to 
examine nucleotide sequence and method patent claims and patent 
prosecution in the context of agricultural biotechnology. Many patents 
claiming rights to nucleotide sequences have also been issued in this 
field. Indeed, it is interesting to note that most of the Australian Patent 
Office decisions to date considering the applicability of the D’Arcy 
holding have concerned non-human nucleotide sequences and method 
claims. The impact of D’Arcy in this context has been largely unexplored 
and warrants further scrutiny. Agricultural biotechnology is an important 
area of innovation in Australia, particularly for government research labs 
and small biotechnology firms. One cause for concern in the study by 
Aboy and colleagues was that the number of small firms owning 
nucleotide sequence-related patents dropped dramatically post-AMP.204 
If a similar trend emerges in Australia this could have significant 
implications for biotechnology innovation in this country. This is an area 
that is of particular research interest to us and in our view warrants 
investigation, with particular focus on the costs and benefits of 
nucleotide sequence and method patent claims. Given that the Federal 
Court’s decision in Meat & Livestock Australia Limited and Dairy Australia 
Limited v Cargill, Inc205 is likely to be appealed to the Full Court, it may be 
worthwhile to delay any further analysis until this case is finally resolved. 
 
8.2 PARTICULAR ISSUES WITH DIAGNOSTIC METHOD CLAIMS 
We have already alluded to the fact that the D’Arcy decision says nothing 
about patent claims to methods of diagnosis and other methods tied to 
nucleotide sequences. Respondents to our surveys and interviews have 
consistently reported less concern for method claims than nucleotide 
                                                           
203  Mateo Aboy et al, ‘Myriad’s Impact on Gene Patents’ (2016) 34 Nature 
Biotechnology 1119. 
204  Ibid 1122. 
205  (2018) 354 ALR 95; [2018] FCA 51. 
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sequence claims per se. From our interviews and other discussions with 
researchers and diagnosticians, we put this down to a concern that this 
subject matter is inherently of the nature of a discovery of something 
that exists in the natural world, not an invention. Methods, it seems, are 
better recognised as having the characteristics of inventions. 
Interviewees in the present study also seemed to accept that there was 
effort and inventiveness involved in developing a new method. Despite 
this, method claims could in fact have greater impact on the genetic 
diagnostic sector. For example, the comprehensive claims analysis 
undertaken by Huys et al found that in many cases diagnostic method 
claims could have a more profound blocking effect on diagnostic testing 
than nucleotide sequence product claims.206 
8.2.1 US Supreme Court case law 
In contrast to Australia, there have been a number of decisions of the US 
Supreme Court relating to method claims that are having a profound 
impact on the scope of patentable subject matter. These include 
computer software methods, computer-implemented business methods 
and diagnostic methods.207 As noted by Nicol in a recent book chapter,208 
in each case, the Supreme Court was particularly concerned that the 
patent claims in issue were apt to pre-empt abstract ideas, laws of nature 
and natural phenomena, long held to be patent ineligible. A summary of 
the key points from that chapter follows.  
Of particular relevance, the Supreme Court in Mayo Collaborative 
Services v Prometheus Laboratories, Inc. (‘Mayo’)209 held that a method 
of comparing and analysing rates of drug metabolism in the human body 
with reference data failed to satisfy the patentable subject matter 
requirement on the basis that it amounted to patenting a law of nature. 
To be patent eligible, another inventive concept would have to be added, 
amounting to something ‘significantly more than a patent upon the 
natural law itself’.210 The conclusion of the Court was that the relevant 
claims included no other elements or combination of elements sufficient 
to ensure that the patent in practice amounted to significantly more than 
a patent upon the natural law itself. The Myriad patents in issue in the 
                                                           
206  Huys et al, above n 190. 
207  Bilski v Kappos, 561 US 593 (2010); Mayo Collaborative Services v Prometheus 
Laboratories, Inc, 566 US 66 (2012) (‘Mayo’); Alice Corporation Pty Ltd v CLS Bank 
International, 134 US 2347 (2014). 
208  Dianne Nicol, ‘Gene Patents’ in Ian Freckleton and Kerry Petersen (eds), Tensions 
and Traumas in Health Law (The Federation Press, 2017) 401. 
209  Mayo, 566 US 66 (2012). 
210  Ibid 1294. 
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AMP litigation included method claims as well as product claims to the 
DNA sequences. The Federal Circuit held that the diagnostic method 
claims were directed towards patent ineligible concepts: abstract mental 
processes with no transformative steps.211 This aspect of the Federal 
Circuit decision was not appealed to the Supreme Court. 
Following Mayo, AMP and other Supreme Court decisions, the USPTO 
developed a broad two-step test for assessing if subject matter 
requirements have been satisfied: 
• Step 1: is the claim directed to a process, machine, manufacture 
or composition of matter? 
• Step 2A: is the claim directed to a law of nature, natural 
phenomenon, or abstract idea? 
• Step 2B: does the claim as a whole clearly not seek to tie up the 
exception?212 
Thus, in the US, patents claiming methods of using subject matter derived 
from the natural or abstract world will be invalid unless the methods 
themselves are truly innovative.  
8.2.2  The Australian High Court on method claims 
In Australia, there has been some recent judicial activity on the 
applicability of the NRDC test to method claims, but this provides limited 
assistance in the context of gene-related methods. The decision of the 
High Court of Australia in Apotex Pty Ltd v Sanofi-Aventis Australia Pty 
Ltd (‘Apotex’) in 2013 (prior to D’Arcy) related to patents for methods of 
medical treatment.213 There has already been a body of case law in 
Australia and other jurisdictions on the patentability of methods of 
medical treatment,214 but prior to this case the High Court had not been 
given the opportunity to directly rule on this question. Four of the five 
judges in Apotex (with Hayne J in dissent215) held that the new use of a 
                                                           
211  See Justice Lourie’s opinion on these issues in the second Federal Circuit decision: 
Association for Molecular Pathology v United States Patent and Trademark Office, 
689 F 3d 1303, 1355 (Fed Cir, 2012) (pages 55-62 of the slip opinion). 
212  United States Patent and Trademark Office, ‘2014 Interim Guidance on Patent 
Subject Matter Eligibility’ (2014) 79(241) Federal Register 74619, 74621.  
213  Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 253 CLR 284; [2013] HCA 50 
(4 December 2013) (‘Apotex’). 
214  Discussed in Justine Pila, ‘Methods of Medical Treatment within Australian and 
United Kingdom Patents Law’ (2001) 24 University of New South Wales Journal 420. 
215  For Hayne J, the key issue is whether the process produces a product that has 
economic value, not whether the process has economic value because people 
Future Issues 
 79 
known drug in issue in this case fulfilled the manner of manufacture 
requirement.  
In explaining the decision in Apotex, the plurality in D’Arcy noted that a 
key factor was whether according patentability would enhance or detract 
from the coherence of the law relating to inherent patentability.216 Their 
Honours concluded that:  
[h]aving regard to the established patentability of 
pharmaceutical products, the exclusion of treatments using 
such products was anomalous and had no stable logical or 
normative basis. … Their inclusion was consistent with the 
existing application of the law and served to enhance its 
coherence.217 
However, in Apotex, Crennan and Kiefel JJ in their joint judgment and, 
separately, Gageler J raised some words of caution about the broader 
question of patentability of other methods of treatment. For them, the 
question of whether or not ‘the activities or procedures of doctors (and 
other medical staff) when physically treating patients’ satisfy the manner 
of manufacture requirement was left to be decided.218 As a consequence, 
method patents that impose restrictions on the physical treatment of 
patients could be subject to challenge for failure to satisfy the subject 
matter requirement in the future. This is unlikely to provide much 
assistance in the case of methods of diagnosis, however, because such 
methods are performed outside of the body, and hence do not involve 
physical treatment as such.  
8.2.3  Justice Beach in Meat and Livestock Australia v Cargill 
Quite how subject matter eligibility will be judged in such cases in 
Australia is yet to be determined, although Justice Beach provided some 
indication of how the Australian judiciary might approach this issue in 
Meat and Livestock Australia v Cargill.219 If his Honour’s opinion is 
anything to go by, it is most unlikely that the Australian courts will adopt 
anything like the Mayo test. He opined that ‘[t]he exposition of the test 
(particularly the second stage (“apply it”) in Mayo is too sweeping for me 
to work out whether I am acting consistently or inconsistently with its 
                                                           
would pay to use it, relying on NRDC for this interpretation: see Apotex (2013) 253 
CLR 284; [2013] HCA 50 (4 December 2013) particularly at [276]–[277]. 
216  D’Arcy (2015) 258 CLR 334, 372 [93]. 
217  Ibid 351 [28]. 
218  Apotex (2013) 253 CLR 284, 384 [287] per Crennan and Kiefel JJ; see also 390 [312] 
(Gageler J). 
219  Meat & Livestock Australia Limited v Cargill, Inc (2018) 354 ALR 95; [2018] FCA 51. 
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spirit’220 when determining what it takes to transform an unpatentable 
law of nature into a patent-eligible application.221 He found himself 
unable to undertake a comprehensive assessment of coherence with 
foreign laws by considering only ‘cherry-picked jurisprudence from one 
jurisdiction’ (the US).222  
Meat and Livestock Australia v Cargill required the Federal Court to 
consider the patent-eligibility of a series of method claims for identifying 
bovine traits from nucleic acid samples using single nucleotide 
polymorphisms (‘SNPs’).223 Justice Beach noted that there was some 
indication in the plurality’s judgment in D’Arcy that, because they were 
not addressing method claims, by implication such claims might be more 
readily viewed as being within the existing boundaries of patentable 
subject matter.224 In regard to Cargill’s method claims, Justice Beach 
distinguished D’Arcy because the claims in Meat and Livestock Australia 
v Cargill were not entirely directed to naturally occurring genetic 
information.225 The case did not just involve looking at a claim to a nucleic 
acid molecule and considering whether the invention should be 
characterised as a chemical structure or as genetic information. Nor did 
the case just deal with claims that involved the discovery of an objectively 
observed correlation between genotype and phenotype; this was only 
the starting point for the analysis of the claims.226 His Honour held that 
the claims in issue involved the practical application of the genetic 
information to a particular use. The claims gave rise to an artificially 
created state of affairs because they involved the taking of a sample and 
analysing that sample to identify SNPs associated with particular traits of 
interest.227 Thus, the claims were ‘within the plain vanilla concept of 
manner of manufacture as outlined in NRDC and Myriad’ and were not 
at the boundaries of patentable subject matter.228 
8.2.4  The NIPT litigation 
Earlier in this occasional paper, we alluded to issues relating to patents 
connected with non-invasive prenatal testing (‘NIPT’). In 1996 
researchers based at Oxford University in the UK discovered a new type 
                                                           
220  Ibid 217 [492]. 
221  Ibid. 
222  Ibid. 
223  Ibid 100–1 [1]–[7]. 
224  Ibid 202 [409]. 
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of DNA in the blood stream of an expecting mother called cell free fetal 
DNA, or cffDNA.229 NIPT utilises the presence of this fetal DNA in the 
maternal circulation. However, it took over ten years for NIPT to become 
a mainstream form of testing for fetal abnormalities, requiring significant 
advances in genomic techniques.230 Commercial development followed 
quickly, and by late 2011 four companies were offering NIPT in the US 
alone. Although the patent landscape for NIPT is growing exponentially, 
the foundational patent arising from the research conducted at Oxford 
University has been the main source of concern for the developing NIPT 
industry because most forms of NIPT are believed to fall within its scope. 
US6258540 and related patents in other jurisdictions was first assigned 
to Isis Innovation Ltd, the technology transfer arm of Oxford University. 
Isis Innovation Ltd awarded worldwide exclusive rights to this patent 
portfolio to Sequenom in 2005 and assigned the patent to Sequenom in 
2014.231 
In June 2016 Sequenom started infringement proceedings in the 
Australian Federal Court against Sonic Healthcare, Australian Clinical Labs 
and Ariosa Diagnostics Inc (‘Ariosa’) in relation to their prenatal assay 
patent. Sequenom claimed that the use of Harmony NIPT, supplied by 
Ariosa, by Sonic Healthcare and Australian Clinical Labs infringes its 
patent. In August 2016 the respondents filed cross-claims for invalidity of 
Sequenom's patent. Included in the grounds is lack of patentable subject 
matter.232 
In the US, the Federal Circuit Court upheld a decision of the District Court 
of California in favour of Ariosa, finding that cffDNA was a naturally 
occurring phenomenon and that the claimed method of using this 
phenomenon was not sufficiently transformative to be patent eligible.233 
The Supreme Court subsequently refused to grant certiorari to hear an 
                                                           
229  Y M Dennis Lo et al, ‘Presence of Fetal DNA in Maternal Plasma and Serum’ (1997) 
350 Lancet 485. 
230  Rossa W K Chiu and Y M Dennis Lo, 'Non-Invasive Prenatal Diagnosis by Fetal Nucleic 
Acid Analysis in Maternal Plasma: the Coming of Age' (2011) 16 Seminars in Fetal 
and Neonatal Medicine 88. 
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appeal from the Federal Circuit decision.234 The Australian litigation will 
give the Federal Court the opportunity to consider for itself how to apply 
our manner of manufacture test to method claims grounded in naturally 
occurring phenomena.  
These issues relating to the NIPT method claims, and diagnostic and 
other method claims more broadly, are important from the policy 
perspective, given the concerns in the US that allowing claims of this 
nature could pre-empt all other uses of the subject matter underpinning 
them. However, given Beach J’s resounding rejection of Mayo in Meat & 
Livestock Australia Limited v Cargill, and given that he is the first instance 
judge in the NIPT litigation, it is unlikely that we will see any marked move 
towards adoption of the preemption doctrine in the Australian courts any 
time soon.  
                                                           
234  ‘Supreme Court Denies Certiorari in Sequenom v. Ariosa’ on Donald Zuhn et al, 
Patent Docs (26 June 2016) <http://www.patentdocs.org/2016/06/supreme-court-
denies-certiorari-in-sequenom-v-ariosa.html>. 
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APPENDIX A 
INTERVIEW QUESTIONS/THEMES 
 
1. Can you explain a bit about your lab/organisation/department 
and its background/function? 
 
2. What is your role in the lab/organisation/department? 
 
3. What tests does your lab perform? 
o Why these tests? 
 
4. How many tests does your lab perform? Can you roughly 
categorise them into test types? 
 
5. How are the tests paid for – who pays and how are they paid? 
 
6. What tests does your lab do in-house and what tests are sent off? 
o How are the costs of tests calculated and charged in each 
case? 
 
7. How does your approach to performing and costing tests differ 
where the test is listed on the MBS? 
 
8. Do patents enter (or have patents in the past entered) into 
decisions about what your lab tests for? 
 
9. Have these decisions changed where patents have expired, or 
changed due to the Myriad decision? 
o Are you aware of any changes in costing practices 
because patents have expired, or due to the outcome of 
the Myriad decision? 
 
10. How have genetic testing technologies changed over time (eg is 
your lab changing to exome sequencing or whole genome 
sequencing)?  
o How does this affect cost? 
o What are the implications of changing technologies in 
this area? 
 
11. Are there any IP issues that have factored into these decisions? 
Appendix 
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12. Does your lab perform NIPT? 
o Do you perform this test under licence? 
o What influenced your lab to offer the test/how long have 
you offered it? 
o What is your understanding of the patent situation in 
relation to this test? 
o How is this particular test costed and charged? 
o Has there been any change in cost since the test was first 
offered? What would you attribute this to? 
